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ABSTRACT 
Dopamine is the most widely distributed catecholamine 
neurotransmitter in the brain.  D2-dopamine receptors (D2R) are one 
member of a receptor class, known as G-protein coupled receptors, which 
transduce cellular signals upon an interaction with dopamine.  Historically, 
it was believed that in schizophrenic patients, an excess of dopaminergic 
signaling at D2R was the cause of psychotic symptoms.  Thus, 
antipsychotics reversed psychosis by blocking excessive dopaminergic 
signaling from D2R.  Sixty years after the introduction of antipsychotic 
drugs, the connection between the anti-dopaminergic activity of these 
drugs at D2R and the suppression of psychotic symptoms remains 
unknown.  Understanding the ways that different molecules mediate 
changes in the ability of D2R to signal and internalize, and thereby affect 
its cellular compartmentalization is critical to our development of potent 
antipsychotic agents with fewer side effects. 
Upon dopamine binding to the receptor, D2R is thought to generate 
an intracellular signal or signals by activating a heterotrimeric α-β-γ G-
protein that is a component of the receptor complex.  In contrast to other G 
protein beta subunits, Gβ5 is a unique beta subunit that has not been 
shown to interact with other heterotrimeric G proteins in vivo.  Previously, it 
was assumed that regulators of G-protein signaling (RGSs, specifically the 
R7 RGS family of proteins) and Gβ5 are required for the physiological 
  
activity of Gβ5.  Here we show that no R7 RGS proteins are required for 
Gβ5 to interact with both compartmentalized and non-compartmentalized 
forms of D2R.  Additionally, we have identified one way that Gβ5 may 
modulate D2R signaling, by specifically blocking the internalization of the 
receptor in response to dopamine without disrupting the G protein 
signaling. 
All currently available antipsychotics have been demonstrated to 
bind to and inhibit D2R receptors.  Despite their strong anti-dopaminergic 
action, the efficacy of antipsychotic agents is limited by the serious side 
effects that these drugs produce, such as tardive dyskinesia and metabolic 
syndromes.  Clozapine, a uniquely efficacious antipsychotic drug, 
produces reductions in schizophrenic symptoms without manifesting the 
common adverse effects of other antipsychotics.  Therefore we have 
reexamined the effects of clozapine on D2R biochemistry, specifically how 
cellular compartmentalization of D2R may be affected by antipsychotic 
treatment.  We found that all antipsychotics tested significantly increased 
the surface localization, as well as enhancing the solubility, of D2R; with 
the sole exception of clozapine.  This new paradigm may explain 
clozapine’s unique therapeutic efficacy.  This discovery could lead to the 
developments of new therapeutic agents that produce less significant side 
effects, and more potent reduction of schizophrenic symptoms than the 
currently available antipsychotic agents
iv 
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PREFACE 
This dissertation was completed in the manuscript format. It is divided into two 
major manuscripts that relate to the understanding how cellular 
microenvironments and protein-protein interactions can affect the signaling of the 
D2-Dopamine receptor.  The first manuscript is a description of how a unique G 
protein beta subunit, Gβ5, can influence the signaling of the D2-Dopamine 
receptor. This manuscript was prepared according to the format guidelines of the 
Journal of Neurochemistry. The second manuscript identifies a novel mechanism 
of action of antipsychotic agents and a distinctive confirmation of the D2-
Dopamine receptor that is produced by the antipsychotic clozapine, an 
exceptionally potent antipsychotic drug. This last manuscript was prepared 
according to the format of the Journal of Biological Chemistry. 
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ABSTRACT 
G beta 5 (Gbeta5, Gβ5) is a unique G protein β subunit that is thought to be 
expressed as an obligate heterodimer with R7 regulator of G protein signaling 
(RGS) proteins instead of with G gamma (Gγ) subunits.  However, here we 
provide data suggesting that Gβ5 can functionally interact with D2R 
independently of R7 RGS proteins.  We found that D2R coexpression enhances 
the expression of Gβ5, but not that of the G beta 1 (Gβ1) subunit, in HEK293 
cells, and that the enhancement of expression occurs through a stabilization of 
Gβ5 protein.  We had previously demonstrated that the vast majority of D2R 
either expressed endogenously in the brain or exogenously in cell lines 
segregates into detergent-resistant biochemical fractions.  We report that when 
expressed alone in HEK293 cells, Gβ5 is highly soluble, but is retargeted to the 
detergent-resistant fraction after D2R coexpression.  Furthermore, an in-cell 
biotin transfer proximity assay indicated that D2R and Gβ5 segregating into the 
detergent-resistant fraction specifically interacted in intact living cell membranes.  
Dopamine-induced D2R internalization was blocked by coexpression of Gβ5, but 
not Gβ1. However, Gβ5 coexpression had no effect on agonist-induced 
internalization of MOR, cell surface D2R levels, dopamine-mediated recruitment 
of β-arrestin to D2R, or the amplitude of D2R-G protein coupling and had only a 
negligible effect on the deactivation kinetics of D2R-activated G protein signals.  
The latter data suggest that direct functional interactions between D2R and Gβ5 
that are not mediated by endogenously expressed R7 RGS proteins. 
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Keywords:  G Beta 5, D2 Dopamine Receptor, G proteins, R7 RGS proteins, 
Detergent Resistant Membrane Compartments, Receptor Regulation 
Abbreviations:  ANOVA, analysis of variance; AP, attenuated acceptor peptide 
with sequence GLNDIFEAQKIE; Arr-BL, β arrestin-2 biotin ligase fusion 
construct; BL, E. coli biotin ligase, BirA; BRET, bioluminescence resonance 
energy transfer; cDNA, complementary DNA; D2R-AP, D2R construct with the 
biotin ligase acceptor peptide insertion into the 3rd cytoplasmic loop; D2R, D2-
dopamine receptor; D4R, D4-dopamine receptor; DAMGO, [D-Ala(2), N-Me-
Phe(4), Gly(5)-ol]-enkephalin; DR, dopamine receptor; FK506, FKBP binding 
protein; FKBP-AP, FK506 binding protein with an attached attenuated acceptor 
peptide; FLAG, FLAG epitope tag; FRB-BL, FKBP-rapamycin binding protein, 
biotin ligase construct; FRB, FKBP-rapamycin binding protein; GAP, GTPase 
accelerating protein; GDP, guanosine diphosphate; GGL, Gγ-like domain; GPCR, 
G protein coupled receptor; GTP, guanosine-5'-triphosphate; GTPase, 
guanosine-5'-triphosphatase; Gαo, G protein alpha (o) subunit; Gβ1, G protein 
beta 1 subunit; Gβ5-BL, G protein beta 5-biotin ligase fusion construct; Gβ5, 
short isoform of the G protein beta 5 subunit; Gβ5L, long isoform of the G protein 
beta 5 subunit; Gβγ-Venus, Gβγ dimer tagged with Venus;  Gβγ, G protein beta-
gamma dimer; Gγ, G protein gamma subunit; HEK293, human embryonic kidney 
cells 293 stably expressing the SV40 T-antigen; HRP, horseradish peroxidase; 
KRAS‑BL, BirA biotin-ligase fusion construct with the membrane-targeting 
domain with the sequence KKKKKKSKTKCVIM from the protein KRAS; 
masGRK3ct-NanoLuc, Gβγ binding peptide from GRK3 fused to an enhanced 
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renilla luciferase; MOR, mu opioid receptor; PBS, phosphate-buffered saline; 
PVDF, polyvinylidene fluoride; RGS, regulator of g protein signaling; RGS9-2, 
regulator of g protein signaling 9-2; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis; t½, half-life of agonist response; TCA, 
trichloroacetic acid; TX100, Triton X-100; V5, V5 epitope tag; ΔBRET, BRET 
signal values corrected with baseline signal 
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INTRODUCTION 
The D2-dopamine receptor (D2R), is a G protein coupled receptor (GPCR) that is 
a major target of drugs used to alleviate symptoms of schizophrenia, Parkinson’s 
disease and depression (Missale et al. 1998; Neve et al. 2004).  Many of the 
cellular actions of GPCRs are mediated via the activation of intracellular 
heterotrimeric G proteins, which consist of a Gα subunit and a protein dimer 
consisting of Gβ and γ subunits.  When an activated GPCR encounters a trimeric 
G protein, it catalyzes the exchange of GTP for GDP at Gα, leading to the 
dissociation Gα subunit from a Gβγ dimer.  The activated GTP-bound Gα subunit 
and the free Gβγ dimer regulate the activity of diverse cellular effector molecules.  
Signal termination is mediated by the intrinsic GTPase activity of the Gα, which 
hydrolyzes the bound GTP to GDP, allowing it to re-associate with the Gβγ 
dimer (Bockaert and Pin 1999; Lagerström and Schiöth 2008). 
Five different G protein Gβ subunits have been identified thus far, of which the 
first four share 80-90% homology (Slepak 2009).  The fifth, Gβ5, is an atypical 
member, and shares only about 50% sequence homology with the first four 
members.  Two alternatively spliced isoforms of Gβ5 have been described.  The 
“short” isoform (Gβ5) is broadly expressed in neural, neuroendocrine and 
excitable tissues while the long isoform (Gβ5L) has only been found expressed in 
retinal photoreceptors.  Severe phenotypes associated with the Gβ5 knockout 
mice, indicate Gβ5 likely has many important and diverse cellular functions.  For 
example, Gβ5 knockout mice have impaired brain development and exhibit 
multiple neurological abnormalities (33–35).  In addition, these mice have altered 
6 
metabolism and abnormal weight regulation, presumably via actions in the 
central nervous system (Wang et al. 2011)  
The GTPase activity of Gα G proteins is enhanced by RGS (regulator of 
G protein signaling) proteins and thus RGS proteins accelerate the rate of GPCR 
signal termination.  All RGS proteins have a conserved core “RGS domain” which 
is necessary and sufficient for their GTPase accelerating protein (GAP) 
function (Ross and Wilkie 2000).  Many RGS proteins also possess additional C- 
and N-terminal domains (Sethakorn et al. 2010; De Vries et al. 1999) that 
mediate diverse functions.   
For example, R7 RGS family proteins contain a Gγ-like (GGL) domain that has 
been shown to specifically bind Gβ5 subunits and enhance GAP function (32, 
38–41).  In fact, it is thought that in vivo, Gβ5 does not form G protein Gβγ 
dimers and that complex formation between Gβ5 and the GGL domain-
containing R7 RGS proteins is necessary for stabilizing both Gβ5 and R7 RGS 
proteins (32, 38–41).  The genetic ablation of Gβ5 resulted in the loss of all R7 
RGS proteins (39), and conversely, Gβ5 protein was not detected in the retina of 
a triple knockout mouse line lacking the R7 RGS proteins, RGS6, RGS7, and 
RGS11 (42).  Furthermore, the Gβ5 long isoform (Gβ5l) that forms a complex 
with the R7 RGS protein, RGS9-1, was absent from the photoreceptors of RGS9 
knockout mice (Chen et al. 2000).   
However, it has not been demonstrated that Gβ5 exists solely as a heterodimer 
with R7 RGS proteins in all tissues where Gβ5 may be expressed.  Alternative 
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proteins, not abundantly expressed in retinal cells, could contribute to stabilizing 
Gβ5 expression in other regions.   
Previously, it has been shown that the complexes of Gβ5 and R7 RGS proteins 
can target to D2R and other GPCRs but these interactions are thought to occur 
through protein domains, such as the DEP domain, that are present within R7 
RGS proteins (44–48).   
Here we report that Gβ5 can functionally interact with D2R in HEK293 cells and 
that D2R coexpression stabilizes Gβ5 to enhance Gβ5 expression.  Moreover, 
the D2R-Gβ5 interaction likely occurs independently of R7 RGS proteins 
suggesting that Gβ5 may have additional cellular functions in addition to its 
established role as a component of the R7-RGS/Gβ5 complex.   
MATERIALS AND METHODS 
Chemicals 
All chemicals and reagents were purchased from Sigma-Aldrich, Fisher Scientific 
or from suppliers that have been specifically identified below. 
Cell Culture and Transfection 
Human embryonic kidney cells (HEK293, American Type Culture Collection) 
were grown in Dulbecco's Modified Eagle Medium supplemented with 10% v/v 
fetal bovine serum, penicillin (100 units/ml) and streptomycin sulfate (100 µg/ml).  
Mammalian expression plasmids containing the appropriate cDNA constructs 
were transiently transfected using LTX transfection reagent (Life Technologies) 
according to the manufacturer’s instructions.  Total transfected DNA was 
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maintained between groups by co-transfecting empty plasmid vector pcDNA 
3.1+ (Life Technologies). 
cDNA Constructs 
All plasmid constructs utilized below were created using standard techniques in 
molecular biology.  The N-terminal FLAG-tagged version of the long form of the 
human D2-dopamine receptor (D2R) (Kearn et al. 2005), the N-terminal FLAG-
tagged D4-dopamine receptor (D4R) (Marley and von Zastrow 2010), the Gβ5 
short isoform construct (Kovoor et al. 2000), the FLAG-tagged D2R construct 
with the biotin ligase acceptor peptide insertion into the 3rd cytoplasmic 
loop (D2R-AP) (Sharma et al. 2013), the E. coli BirA biotin-ligase fusion construct 
with the membrane targeting domain of KRAS (KRAS-BL, and the β-arrestin-2 
biotin ligase fusion construct (Arr-BL) (Sharma et al. 2013) have previously been 
described.  The D2R-AP construct consists of the FLAG-tagged D2R into which 
an attenuated acceptor peptide sequence (GLNDIFEAQKIE) is inserted between 
amino acids at position 305 and 306 in the 3rd cytoplasmic loop.  KRAS-BL 
consisted of the following peptide sequences in order from the N to the C-
terminus: the V5 epitope-tag, the BirA E. coli biotin ligase enzyme (BL), a 
GSGSG linker and a membrane targeting peptide sequence 
(KKKKKKSKTKCVIM) from the protein KRAS.  Arr-BL consisted of the following 
peptide sequences in order from the N to the C terminus, β-arrestin-2, a GSGSG 
linker, and the BirA an E. coli biotin ligase enzyme (BL).  The N-terminal FLAG-
tagged human G protein Gβ1subunit was obtained from the Missouri S&T cDNA 
Resource Center (catalog #: GNB010FN00).  The G protein beta 5-biotin ligase 
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fusion (Gβ5-BL) was created by attaching the BirA biotin ligase enzyme to the N-
terminus of the full-length Gβ5 short isoform via a two amino acid linker. Thus, 
the fusion protein in order from N to C terminus consists of BirA, an Arg-Tyr 
linker, the Gβ5 short isoform, and a V5 epitope tag.  The cDNA for the E. coli 
biotin ligase, BirA (BL), was provided by Dr. Alice Ting (Massachusetts Institute 
of Technology) and was amplified by PCR.  Diagrams of these constructs are 
provided in Fig. 4A and 7A.   
Triton X-100 Biochemical Fractionation of Proteins 
The method for the Triton X-100 (TX100) biochemical fractionation of proteins 
has been adapted from our previous publication (Celver et al. 2012).  Briefly, 48 
hr post transfection cells were lysed in TX100 lysis buffer (phosphate-buffered 
saline, in mM: 137 NaCl, 2.7 KCl, 10 Na2HPO4, 2 KH2PO4, pH 7.4 (PBS) 
containing 2% v/v of the non-ionic detergent, Triton X-100) and a 1× 
concentration of SigmaFast Protease inhibitor (made according to manufacturer’s 
instructions, Sigma-Aldrich) for 1 hr at 4 ºC The samples were 
centrifuged (10,000 g, 10 min at 4 ºC) to pellet the insoluble proteins.  
Supernatant proteins (i.e. the TX100-soluble fraction) were precipitated by the 
addition of trichloroacetic acid (TCA, final concentration 10% v/v).  Supernatant 
proteins were washed 3× with ice-cold 95% v/v acetone (4 °C).  Both the TX100-
soluble and the insoluble proteins were re-suspended in equal volumes of SDS 
sample buffer (2% w/v SDS, 0.01% w/v bromophenol blue, 8 M urea, 
20 mM dithiothreitol, 50 mM Tris-HCl, pH 6.8).  Samples were sonicated 25× for 
approximately 0.5 s at power setting of 10 for ~0.5 s to reduce sample viscosity 
10 
prior to loading using a sonicator (XL-2000, qSonica).  Equal volumes of the 
samples were then resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and the relative levels of protein expression were 
then compared by Western blotting. 
Protein Degradation Assay 
To determine the effect of D2R on the rate of degradation of Gβ5 we used 
cycloheximide, a translational inhibitor, to block protein synthesis and then 
measured the amount of Gβ5 present in cells at 3 and 6 hr after the addition of 
cycloheximide. 2.5 × 105 HEK293 cells were transfected with appropriate cDNA 
plasmids containing Gβ5 with or without D2R in a 24 well plate. At 48 and 51 hr 
post-transfection selected wells were treated with 100 µM 
cycloheximide (time = 6 and 3 hr cycloheximide treatment, respectively). After 
incubation for 3 hr (54 hr post-transfection) all cell samples were harvested in 
media from multi-well plates using a micropipetter. Cells were spun down for 5 
minutes at 300 × g using a bench top centrifuge and carefully washed 3 × with 
cold (4 °C) PBS. Washed cells were then lysed by sonication on ice after being 
resuspended in equivalent volumes of SDS sample buffer. Protein samples were 
then incubated for 15 min at 65 °C resolved by SDS-PAGE. 
Biotinylation of D2R-AP by Biotin Ligase Fusion Proteins 
We utilized an in cell biotin transfer assay to detect whether or not Gβ5 interacted 
with detergent soluble or insoluble forms of D2R. The plasmids containing 
cDNAs for D2R-AP, Gβ5-BL or KRAS-BL as described in Figure 5A were 
11 
transfected into HEK293 cells in biotin-free media.  48 hr post-transfection, 
10 µM biotin was added to the media. After 2 minutes of incubation at 25 °C, the 
cells were washed 3 × using ice-cold (4 °C) 1 × PBS.  The cells were then 
vigorously resuspended in ice-cold 2% v/v TX100 lysis buffer and incubated for 
1 hr at 4 °C, with vortexing every 15 minutes.  Soluble and insoluble proteins 
were then harvested using the method as described in the “Triton X-100 
Biochemical Fractionation of Proteins” section. 
We also used the biotinylation assay to detect recruitment of β-arrestin 2 to D2R 
after dopamine stimulation. The plasmids for D2R-AP and Arr-BL with or without 
Gβ5 (Fig. 8A) were transfected into HEK293 cells growing in biotin-free media. 
48 hours post-transfection, cells were treated with 10 µM dopamine or vehicle for 
30 min. Subsequently, the media containing dopamine was removed, the cells 
were washed 2 × with cold (4 °C) PBS, and then were treated with 10 µM biotin 
in 1 × PBS for 2 minutes.  Cells were then washed 3 × with ice-cold PBS and 
then lysed in SDS sample buffer. 
Samples were then resolved by SDS PAGE. The proteins were then transferred 
to methanol-wetted polyvinylidene fluoride (PVDF) membranes and probed with 
streptavidin conjugated to horseradish peroxidase (HRP).  These procedures and 
reagents are described in the “Western Blotting” section below.   
Western Blotting 
Proteins were resolved by gel electrophoresis and then transferred to methanol-
wetted PVDF membranes by Western blotting apparatus (IBI Scientific) using 
electrophoresis buffer (25 mM Tris base, 192 mM glycine, 20% v/v methanol, pH 
12 
~8.3).  For antibody-based detection, PVDF membranes (Immobilon-FL, EMD 
Millipore) were blocked by incubation with 5% w/v nonfat dry milk reconstituted in 
PBS (1 hr at 20 ºC).  For the detection of biotinylated proteins, membranes were 
blocked by incubation in 3% w/v bovine serum albumin in PBS (1 hr at 20 ºC).  
V5 epitope-tagged proteins (KRAS-BL and Gβ5-BL) were detected by incubating 
blots with an HRP-conjugated anti-V5 antibody (Invitrogen/Life Technologies, 
1:5000 in 5% w/v nonfat milk in PBS).  FLAG epitope-tagged protein 
bands (D2R, D4R, and MOR) were detected by incubating blots with an HRP-
conjugated mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, 1:5000 
dilution in 5% w/v nonfat milk in 1 × PBS).  Biotinylated protein (D2R-AP) bands 
were detected by incubating blots with HRP-conjugated streptavidin (1:10,000 in 
1 × PBS containing 3% w/v BSA).  Gβ5 was detected by incubating blots with 
rabbit polyclonal antibody CT215 (1:5000 in PBS containing 5% w/v nonfat 
milk) (Watson et al. 1996; Watson et al. 1994).  After incubation with the primary 
antibodies or HRP-conjugated streptavidin the blots were washed 3× in PBS 
containing 0.1% v/v tween-20 (PBS-T).  If the primary antibody was not directly 
conjugated to HRP the membrane was then incubated with appropriate HRP-
conjugated secondary antibodies (Jackson ImmunoResearch, Inc.) and washed 
4× in PBS.  
Chemiluminescent signals produced by the HRP enzyme were obtained using 
Supersignal West Femto substrate and detected using a Chemidoc XRS 
Molecular Imager (Bio-Rad Laboratories).  To directly compare the signals from 
the TX100-soluble and insoluble fractions of a cell sample, the proteins from 
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these fractions were loaded onto the same SDS-PAGE gel and transferred to a 
single immunoblot.  Protein samples were serially diluted and the signals 
quantified to ensure that the concentrations used for experiments was in the 
linear range of the signal-protein function. 
Fast Kinetic BRET Assay 
The agonist effects of dopamine on G protein signaling in cells expressing D2R 
was measured using a fast kinetic BRET assay (Masuho et al. 2013).  BRET was 
measured between masGRK3ct-NanoLuc and Gβ1γ2-Venus in living cells as 
previously described BRET measurements were made at room temperature 
using a microplate reader (POLARstar Omega, BMG Labtech) equipped with two 
emission photomultiplier tubes, with a maximum of 50 milliseconds resolution.  
The BRET ratio is calculated by dividing the light emitted by Gβ1γ2-Venus (535 
nm) over the light emitted by masGRK3ct-NanoLuc (475 nm). The average 
baseline value recorded prior to agonist stimulation was subtracted from BRET 
ratio values, and the resulting difference (ΔBRET) was obtained.  The amplitude 
of the dopamine response was the maximal ΔBRET ratio achieved after 
application of 10 nM dopamine.  The time constants for signal deactivation were 
derived from single exponential fits of the deactivation curve following application 
of 100 µM haloperidol.  Kinetic analysis and curve fitting were performed using 
pCLAMP 6 software (Molecular Devices).  
Receptor Internalization Assay 
To determine the effect of overexpression of Gβ subunits (Gβ1 or Gβ5) on 
receptor internalization we used an ELISA-based assay to determine the amount 
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of receptor present at the plasma membrane after the application of dopamine. 
Day 1, 5 × 104 HEK293 cells were transfected with appropriate cDNA plasmids 
containing D2R with or without Gβ1 or Gβ5 or MOR with or without Gβ5, in a 96-
well plate.  48 hours post-transfection cells were treated with a saturating 
concentration (50 µM) of dopamine in the case of D2R or DAMGO in the case of 
MOR for 45 minutes.  The media was then aspirated, and cells were gently 
washed 3 times with cold (4 °C) PBS.  Cells were then fixed with 4% v/v 
formaldehyde in PBS, and then washed 3 times with PBS.  Wells were blocked 
for 30 minutes with 5% nonfat milk dissolved in PBS.  Surface receptor was then 
probed for using HRP-conjugated mouse monoclonal anti-FLAG M2 
antibody (1:5,000 dilution in 5% nonfat milk in PBS) for 1 hour at 37 °C and then 
washed 3 × with PBS.  Supersignal West Femto chemiluminescent 
substrate (Pierce-Thermo Fisher Scientific) was then applied to each well and 
signals were detected and quantified using a multi-well plate compatible 
luminometer (Glomax) and attached computer. 
Data Analysis 
Signals from the target protein bands were quantified using ImageJ image 
processing and analysis software (National Institutes of Health, Bethesda, MD, 
http://rsbweb.nih.gov/ij/).  Statistical analyses were performed using Microsoft 
Excel or GraphPad Prism 4 software (GraphPad Software, Inc.).  Images were 
collected using exposure settings that did not saturate any of the pixels acquired 
by the camera.  The signals resulting from detergent-soluble and insoluble 
preparations of a protein, respectively, were expressed as a fraction of the total 
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signal and Student's t-test for independent means of unequal variance was used 
to determine if the amounts of signal from the target protein bands in each 
experimental group were significantly different.  When testing the significance of 
means for more than 2 experimental groups, one-way ANOVA was used to first 
determine group statistical significance and only followed by Tukey’s post-hoc 
analysis if the initial comparison was found to be significant. 
RESULTS 
Coexpression of D2R in HEK293 cells enhances the detergent-resistance of Gβ5 
even in the absence of exogenous coexpression of R7 RGS proteins.   
We had previously shown that the vast majority of D2-dopamine receptors (D2R) 
expressed endogenously in the brain, or exogenously in the plasma membrane 
of cell lines, segregates into cellular fractions that are resistant to solubilization in 
non-ionic detergents (Celver et al. 2012) and we showed that this detergent-
resistant D2R fraction is functional and responds to dopamine (Sharma et al. 
2013).  Furthermore, coexpression of D2R produces translocation of putative 
D2R interacting proteins, such as the RGS9-2/Gβ5 complex and G proteins, from 
detergent-soluble to detergent-resistant membrane fractions when the latter 
proteins are expressed in cell lines (Celver et al. 2012; Sharma et al. 2013).  In 
fact, interactions with D2R, which is expressed at relatively high concentrations in 
the striatum compared to the cortex (Missale et al. 1998; Neve et al. 2004), could 
explain why we and others have found that the endogenous striatal RGS9-2/Gβ5 
complex is resistant to detergent-extraction, but the same complex when 
expressed in cell lines is highly soluble (Celver et al. 2012; Mancuso et al. 2010).   
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To provide further support for the idea that targeting to D2R can contribute to 
enhanced detergent resistance of D2R-interacting proteins the striatum, we 
compared the detergent-solubility of Gβ5 endogenously expressed in mouse 
striatum and the cortex.  We found that the percent of striatal Gβ5 that was 
extracted into cold solutions (4 °C) of the non-ionic detergent Triton X-100 was 
almost halved (from ~40% to 20%), relative to Gβ5 extracted from the 
cortex (Celver et al. 2012).   
One explanation for the increased detergent-resistance of striatal Gβ5 is that 
D2R, which we have shown is highly resistant to detergent solubilization, is 
expressed at high concentrations in the striatum compared to the cortex and Gβ5 
is then targeted to the detergent-resistant striatal D2R through an interaction with 
RGS9-2 or other R7 RGS proteins (Celver et al. 2012).  Therefore, in a control 
experiment using HEK293 cells, we tested if D2R could enhance the detergent-
resistance of Gβ5 independently of exogenously expressed R7 RGS proteins.  
We found that coexpression of D2R with Gβ5 in HEK293 cells significantly 
increased the percent of Gβ5 that segregated into the TX100-insoluble cellular 
fraction (from ~40% to 70%), even in the absence of exogenously coexpressed 
R7 RGS protein constructs (Fig. 1A and B).  This is a surprising result, because 
while endogenous expression of R7 RGS proteins in HEK293 cells has been 
suggested via RNA interference (Laroche et al. 2010), a microarray analysis of 
mRNA levels of GPCR related signaling proteins expressed in these cells did not 
detect statistically significant levels of mRNA for any of the R7 RGS 
proteins (Atwood et al. 2011).  Thus, transiently expressed Gβ5 protein, is likely 
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to vastly exceed the endogenously expressed levels of R7 RGS family members 
in HEK293 cells.   
Coexpression of Gβ5, on the other hand, did not significantly affect the TX100-
solubility of D2R protein (% D2R that was soluble when expressed alone was 
21.8 ± 4.7, and after Gβ5 coexpression was 30.8 ± 5.4, n = 4, p > 0.05, data not 
shown).  Figures 1C and D illustrate, as reported earlier (Celver et al. 2012; 
Sharma et al. 2013), that the majority (>70%) of coexpressed D2R protein 
segregates into the TX100-insoluble fraction.  
Dopamine pretreatment (10 µM for 30 min) had no effect the TX100-solubilitiy of 
Gβ5.    
We report that the closely related D2-like dopamine receptor, D4R, also 
segregates into the TX100-insoluble cellular fraction and that Gβ5 is similarly 
retargeted to the TX100-insoluble cellular fraction after D4R 
coexpression (Fig. 1A, B, C and D).   
The above phenomenon is specific to dopamine receptors as we have previously 
reported that coexpression of the mu opioid receptor (MOR) did not affect the 
detergent-solubility of either component of the R7 RGS protein-Gβ5 
complex (Celver et al. 2012).   
The other, more canonical G protein Gβ subunits are intrinsically resistant to 
detergent solubilization (Rehm and Ploegh 1997), and thus a similar D2R-
mediated retargeting of other Gβ subunits, such as Gβ1, to the TX100-insoluble 
cellular fraction was not observed (Fig. 1E and F).   
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D2R coexpression specifically enhances the expression and stability of Gβ5.   
In addition to translocating Gβ5 to the TX100-insoluble fraction we observed that 
the coexpression of D2R simultaneously and dramatically increased the cellular 
expression of Gβ5 protein (Fig. 1A, 2A and B, and 3A).   
The actions of D2R in increasing Gβ5 expression levels were specific.  First, 
coexpression of D2R increased expression levels of Gβ5 by more than 400%, 
but, in contrast, coexpression of another GPCR, the mu opioid receptor (MOR) 
did not significantly alter expression levels of Gβ5 (Fig. 2A and B).   
Second, the expression level of the G protein Gβ subunit, Gβ1, was instead, 
significantly decreased after D2R coexpression (Fig. 2C and D).   
To explore if D2R-mediated stabilization of Gβ5 contributed to the enhanced Gβ5 
expression observed after D2R expression, we treated HEK293 cells expressing 
Gβ5 alone, or coexpressing D2R and Gβ5, with cycloheximide, a protein 
translation/synthesis inhibitor, and the decay of the cellular Gβ5 protein signal 
after cycloheximide treatment for 3 and 6 hr was monitored by Western blotting.  
We found that coexpression of D2R significantly decreased the decay of the Gβ5 
signal observed at both 3 and 6 hr (Fig. 3).  For example, after 6 hr of 
cycloheximide treatment, the levels of Gβ5 protein in cells expressing Gβ5 alone 
had decayed to less than 30%, but in cells coexpressing D2R greater than 60% 
of the original Gβ5 signal remained (Fig. 3).  Thus, D2R coexpression 
significantly inhibited the cellular degradation of Gβ5.   
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An “in-cell biotin proximity biotinylation assay” indicates physical interactions in 
living cells between D2R and Gβ5 molecules that segregate into the detergent-
insoluble cellular fraction.   
Traditional coimmunoprecipitation techniques (Berggard et al. 2007) for probing 
for either direct or indirect physical interactions between D2R and Gβ5 first 
require solubilizing the proteins in non-ionic detergents that preserve protein-
protein interactions.  Since the vast majority of D2R segregates into a cellular 
fraction that is insoluble in non-ionic detergents (e.g. TX100) it was not feasible 
for us to probe for DR interactions using coimmunoprecipitation.  Furthermore, 
we were unable to coimmunoprecipitate D2R and Gβ5 molecules segregating 
into the TX100-soluble fraction, possibly due to the relatively low concentration of 
D2R molecules that segregate into this fraction.    
Thus, to assess D2R and Gβ5 interactions, we utilized a novel in-cell proximity 
biotinylation assay involving the E. coli biotin ligase, BirA (Fernandez-Suarez et 
al. 2008; Sharma et al. 2013), which specifically biotinylates a unique “acceptor 
peptide” sequence, not present in mammalian proteins.  An attenuated 
biotinylation acceptor peptide substrate sequence (denoted here as AP) was 
inserted into the 3rd cytoplasmic loop of D2R (D2R-AP), while the BirA biotin 
ligase enzyme (BL) was fused to either Gβ5 (Gβ5-BL) or a peptide motif from 
KRAS (KRAS-BL) (Fig. 4A).  The D2R-AP substrate and the biotin ligase enzyme 
fusions were co-expressed in HEK293 cells cultured in biotin-depleted medium.  
Following a brief (2 min) treatment of the intact living cells with biotin, the cells 
were lysed in cold (4 °C) TX100 lysis buffer and separated into TX100-soluble 
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and insoluble fractions.  Biotinylation of D2R-AP provides evidence for 
interactions between the D2R-AP substrate and biotin ligase-containing fusion 
that had previously occurred in the intact living cell.   
The use of the technique to evaluate the level of interaction between two proteins 
in living cells has been previously validated.  For example, the rapamycin-
induced interaction between the FKBP (FK506 binding protein) and FRB (FKBP-
rapamycin binding protein) protein pair could be detected by enhanced in-cell 
biotinylation of the FKBP-AP fusion substrate by an FRB-BL fusion (Fernandez-
Suarez et al. 2008).  Similarly, we found that the in-cell biotinylation of D2R-AP 
fusions by a β-arrestin2-BL fusion protein was enhanced by treatment of the cells 
with dopamine (Sharma et al. 2013).   
We had reported earlier that the insertion of the AP-tag into D2R does not greatly 
affect its detergent solubility (Sharma et al. 2013) and that the vast 
majority (~80%) of the D2R-AP construct segregated into the TX100-insoluble 
cellular fraction.  We also showed previously, that when D2R-AP fusion 
substrates and a wide variety of peptide motifs and cellular proteins fused to the 
biotin ligase enzyme were coexpressed in HEK293 cells, in almost every case, 
the majority of the biotinylated D2R-AP substrate segregated into the TX100-
soluble fraction (Sharma et al. 2013).  In other words, biotinylated D2R-AP 
constructs segregated into the TX100-soluble fraction, even though vast majority 
of the parent D2R-AP substrate protein localized into the TX100-insoluble 
fraction (Sharma et al. 2013).  These results indicate that the detergent-resistant 
D2R, though functional and expressed in the plasma membrane, as we 
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previously showed (Sharma et al. 2013), represents receptor that is 
compartmentalized from interacting non-specifically with other cellular proteins.  
On the other hand, the detergent-soluble D2R, which represent a minority of the 
cellular D2R, likely originates from a more fluid region of the cell membrane and 
can interact randomly with other cellular proteins according to the fluid mosaic 
model of Singer and Nicolson (Singer and Nicolson 1972).   
In accordance with the above results, we show that the majority (~70%) of 
D2R-AP that was biotinylated by KRAS-BL segregates into the TX100-soluble 
fraction (Fig. 4B and C). However, we found that the segregation of D2R-AP 
biotinylated by Gβ5-BL, more closely matched the segregation of the parent 
protein with ~70% of biotinylated D2R-AP segregating into the TX100-insoluble 
fraction (Fig. 4B and C).  These results may be interpreted to suggest that 
1) D2R segregating into the TX100-resistant cellular fraction (i.e. the majority of 
the plasma membrane-expressed D2R) is not compartmentalized from Gβ5 as it 
was from KRAS and many other cellular proteins and, 2) that Gβ5, unlike other 
cellular proteins, efficiently interacts in living cells with D2R molecules that 
segregate into both TX100-soluble and insoluble cellular fractions (Fig. 4D).    
Effect of coexpression of Gβ5 on cellular coupling between D2R and Gαo G 
proteins.   
We then tested if the coexpression of Gβ5 could alter the cellular functions of 
D2R.  To test the effects of Gβ5 coexpression on D2R-mediated G protein 
activation we utilized a bioluminescence resonance energy transfer (BRET) 
based assay, recently developed by Hollins and colleagues(Hollins et al. 2009), 
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which measures the release of free Gβγ subunits from the activated G protein.  
The BRET pair that is utilized is the Gβγ dimer tagged with Venus (Gβγ-Venus) 
and masGRK3ct-NanoLuc, a Gβγ binding protein construct fused to a newly 
engineered luciferase variant (64).  The use of this system to monitor coupling 
between D2R and associated G proteins has been described in detail in a 
previously published study (Masuho et al. 2013).  The following proteins were 
coexpressed in HEK293 cells: D2R, the D2R coupled G protein subunit, Gαo, a 
Gβγ fusion with the yellow fluorescent protein Venus (Gβγ-Venus) and 
masGRK3ct-NanoLuc, a fusion of Gβγ binding peptide from the protein, GRK3, 
with a luciferase variant, NanoLuc, are transiently coexpressed in HEK293 cells.  
Activation of the coexpressed G proteins by dopamine-bound D2R results in the 
release of the Venus-tagged Gβγ subunits and interaction with the BRET partner, 
the NanoLuc-tagged masGRK3ct reporter, to produce the BRET signal.  
Subsequent application of the D2R antagonist, haloperidol, allows for the 
reversal of G protein activation and results in BRET signal decay which can be 
well fitted by single exponentials.  No significant dopamine-elicited response was 
observed in cells not transfected with cDNA for either D2R or Gαo (Masuho et al. 
2013) indicating that the BRET signal results from the activation of exogenously 
expressed Gαo G proteins by D2R. 
Under our assay conditions the amplitude of the D2R-elicited Gαo response 
saturates at concentrations higher than 1 µM dopamine (Masuho et al. 2013).  
Using this assay system and a concentration of dopamine of 1 nM we found that 
coexpression of either of two different Gβ5 concentrations had no effect on the 
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amplitude of the dopamine and D2R-elicited BRET response (Fig. 5A and B).  
The inability to detect an effect of Gβ5 on the D2R-elicted response amplitude 
was not due to saturation of the BRET signal as we confirmed, in the same cells, 
that the dopamine concentration (10 nM) was sub-saturating.  Thus, Gβ5 has no 
effect on the efficacy of coupling of D2R to associated Gαo G proteins.   
We then examined the effects of Gβ5 coexpression on the deactivation kinetics 
of D2R-Gαo G proteins signaling where the dopamine signal was reversed by the 
application of 100µM haloperidol.  At the lower level of Gβ5 expression, obtained 
using Gβ5 cDNA transfection concentrations that were similar to those utilized 
the biochemistry experiments described above, no significant effect of Gβ5 was 
observed on the deactivation kinetics (Fig. 5A and C).  However, with much 
higher Gβ5 protein concentrations (> 3X), a small but significant acceleration of 
the deactivation kinetics was detected.   
Coexpression of Gβ5, but not Gβ1, inhibits agonist-induced internalization of 
D2R, and Gβ5 coexpression does not affect agonist-induced internalization of 
MOR   
To quantify receptor internalization we measured the amount of receptor at the 
surface of HEK293 cells both before and after agonist treatment through a 
modification of a previously described enzyme-linked immunosorbent assay 
(ELISA)-based protocol (see Materials and Methods) (Celver et al. 2010).  
Coexpression of Gβ5 had no significant effect on the levels plasma membrane 
expressed D2R or MOR, while coexpression of Gβ1 produced a moderate but 
significant increase in surface expressed D2R (Fig. 6A and B).   
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Treatment of cells transiently expressing D2R or MOR for 45 min with super-
saturating concentrations (10 µM) of the receptor agonists, dopamine or 
DAMGO, respectively, significantly reduced cell surface levels of the respective 
receptors (Fig. 6C and D).  Coexpression of Gβ1 had no effect on the loss of cell 
surface D2R produced by dopamine treatment.  In contrast, coexpression of Gβ5 
completely blocked the dopamine-induced internalization of D2R (Fig. 6C) but 
had no effect on DAMGO-induced internalization of MOR (Fig. 6D).   
Coexpression of Gβ5 does not affect the dopamine-dependent recruitment of 
arrestin to D2R. 
The canonical model for the agonist-induced internalization of many GPCRs 
involves the recruitment, to the agonist-bound GPCR, of β-arrestins, which then 
serve to physically bridge the receptor to the cellular endocytotic 
machinery (Drake et al. 2006).  To determine whether Gβ5 inhibited dopamine-
induced D2R internalization by suppressing recruitment of β-arrestin we used the 
in-cell proximity biotin-transfer assay to evaluate the actions of Gβ5 on this 
process.  In this assay D2R-AP and a fusion construct of β-arrestin2 and the 
E. coli biotin ligase BirA (Arr-BL) (Fig. 7A) are transiently expressed in HEK293 
cells and dopamine treatment (10 µM for 30 min) significantly enhances the Arr-
BL-mediated biotinylation of D2R-AP (Sharma et al. 2013) (Fig. 7B and C).  
However, coexpression of Gβ5 had no effect on D2R-AP biotinylation suggesting 
that Gβ5 did not inhibit recruitment of β-arrestin to D2R.   
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DISCUSSION 
D2R-Gβ5 interactions can occur independently of R7 RGS proteins.   
Several lines of investigations have led to the supposition that Gβ5 is found 
expressed only as a heterodimer with R7 RGS family proteins (32, 38, 39, 42, 
43).  However, none of these experiments have excluded the possibility that 
alternative proteins could contribute to stabilizing Gβ5 expression in other tissue.  
The data presented here, using HEK293 cells, suggest the novel hypothesis that 
D2R can interact with and stabilize the Gβ5 protein, independently of R7 RGS 
proteins.   
Complexes of Gβ5 and R7 RGS proteins can target to D2R and other GPCRs 
and these interactions are mediated through the domains present in the R7 RGS 
protein such as the DEP domain (44–47).  However, the D2R-Gβ5 interactions 
reported here likely occur independently of R7 RGS protein for the following 
reasons.   
Atwood and colleagues have conducted a microarray screen for G protein 
coupled receptors (GPCR) and related signaling molecules that are 
endogenously expressed in HEK293 cells and found that the detected levels of 
transcripts for R7 RGS family members were below levels deemed to be 
statistically significant (Atwood et al. 2011).  Thus, stoichiometrically, the levels of 
Gβ5 transiently expressed in HEK293 cells likely far exceed the levels of any 
endogenously expressed R7 RGS proteins.   
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Furthermore, we have shown that endogenous expression of Gβ5 is not detected 
in HEK293 cells (Celver et al. 2012), and multiple groups, including ours, have 
shown that, in heterologous expression systems, the observed GTPase 
accelerating protein (GAP) function of R7 RGS proteins is dramatically 
enhanced (over 3 fold) by transient coexpression of Gβ5 (40, 55, 67, 68).  The 
Gβ5 enhancement of GAP function likely occurs through multiple mechanisms 
including 1) direct conformational alteration of R7 RGS proteins that promote 
GAP function, 2) through an increase in expression of R7 RGS proteins and 
3) by facilitating the interaction of R7 RGS proteins with membrane 
anchors (Keren-Raifman et al. 2001; Masuho et al. 2011).  Thus, if a significant 
proportion of the exogenously expressed Gβ5 associates with endogenously 
expressed R7 RGS proteins it is expected that the formation of such a complex 
should substantially accelerate the deactivation kinetics of D2R-G protein 
coupling.  However, such an acceleration was not observed (Fig. 5A and C).   
We have previously reported that when R7 RGS proteins, such as RGS9-2, and 
Gβ5 are transiently expressed in HEK293 cells, D2R co-expression does not 
significantly alter protein expression levels of either the R7 RGS protein or Gβ5.  
In other words when Gβ5 is present in a complex with R7 RGS proteins, D2R 
coexpression does not enhance or stabilize Gβ5 protein expression.  However, 
here we have reported that D2R coexpression can dramatically enhance levels of 
transiently coexpressed Gβ5 protein (Fig. 1A, 2A and B, and 3A), indicating that 
Gβ5 is not in a complex with endogenously expressed R7 RGS proteins.   
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Thus, our data suggest that, in HEK293 cells, D2R interacts either directly or 
indirectly with Gβ5, but in a manner that is independent of R7 RGS proteins.  It is 
not clear from our data however if D2R is interacting with the Gβ5 monomer or 
with a complex of Gβ5 with other cellular proteins such a G protein Gγ subunits.   
The D2R-Gβ5 interaction has functional consequences and can bias D2R 
signaling. 
We found that 1) the interaction stabilized and enhanced Gβ5 expression and 
2) the interaction inhibited dopamine-induced D2R internalization but did not 
affect the coupling of D2R to G proteins or the dopamine-mediated recruitment of 
β-arrestin to D2R.     
The biased actions of Gβ5 in altering D2R cellular functions are particularly 
interesting.  It is now apparent that endogenous agonists may stabilize multiple 
receptor conformation and the agonist-bound receptor conformation that 
promotes G protein activation may be different from the conformation that allow 
for agonist-induced internalization of the receptor (Kenakin 2007; Reiter et al. 
2012).  In fact, biased synthetic D2R agonists have been developed that activate 
non-canonical G protein-independent cellular signals but do not promote D2R-
elicited G protein signals (72).  However, we believe that this is the first report of 
a GPCR-interacting cellular protein that modulates the receptor to abolish 
agonist-induced internalization but does not affect D2R-G protein coupling.   
The abolition of dopamine-induced D2R internalization by Gβ5 was not through 
suppression of interactions with β-arrestin, as Gβ5 did not alter  baseline 
interactions of D2R with β-arrestin or dopamine-induced recruitment of β-arrestin 
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to D2R (7B and C).  Gβ5 had no effect on MOR internalization indicating that the 
prevention of D2R-internalization by Gβ5 likely occurs through targeting of Gβ5 
to D2R and is not a consequence of non-specific disruption of the cellular 
internalization machinery.  One model that may be suggested is that 
internalization of D2R requires one or more bridges between D2R and the 
cellular internalization, that are in addition to that made through β-arrestin, and 
Gβ5 expression disrupts such additional connections.   
The expression of D2R in detergent-insoluble plasma membrane 
microcompartments (Sharma et al. 2013) and the targeting of Gβ5 to these 
microcompartments did not require dopamine pretreatment, indicating that Gβ5 is 
preassembled in a manner that allows Gβ5 to edit the actions of dopamine at 
D2R.   
D2R-Gβ5 interactions specific and are not caused by non-specific aggregation of 
the two proteins.   
Coexpression of Gβ5 did not alter either the cell surface levels of D2R, the 
fraction of D2R expressed at the cell surface or the amplitude of D2R-G protein 
coupling, but clearly inhibited dopamine-induced D2R internalization.  These 
observations indicate that the interaction with D2R and stabilization of Gβ5 was 
not caused by non-specific aggregation of the two proteins.   
The majority of the D4-dopamine receptor, which is a member of the D2-like 
dopamine receptor family, also segregates into detergent-resistant cellular 
fractions and recruits Gβ5 to the same biochemical fraction.  However, these 
interactions are unique and do not extend to other cell-expressed GPCRs such 
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as mu opioid receptors (MOR), the vast majority of which are readily solubilized 
in non-ionic detergents (Celver et al. 2012).  In addition, D2R coexpression does 
not significantly alter the detergent-solubility of Gβ1 (Fig. 1E and F) or enhance 
cellular Gβ1 expression levels (Fig. 2C and D).  
Here we have provided evidence for a novel and specific interaction of Gβ5 that 
is significant because it suggests that Gβ5 can directly modulate D2R, an 
important GPCR, to bias D2R to signal canonically through G proteins but can 
prevent dopamine-induced receptor internalization.   In addition our data 
suggests that Gβ5 may be stabilized by protein partners other than R7 RGS 
proteins.  Nevertheless, these experiments were performed in HEK293 cells 
where concentrations of both D2R and Gβ5 are likely to be higher than that found 
in native tissue.  Hence, definitive in vivo evidence for the above supposition will 
require further investigations such as the examination of Gβ5 levels in D2R-
expressing cells in mice where all four R7 RGS protein genes are knocked out. 
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Fig. 1.  Targeting of Gβ5 to the TX100-insoluble fraction upon coexpression of 
D2-like dopamine receptors, D2R and D4R.   
A.  Representative image of a Western blot depicting the segregation of Gβ5 into 
TX100-soluble (S) and insoluble (I) biochemical fractions prepared from HEK293 
cells transfected with cDNAs for the indicated proteins.   
B.  Quantification of the relative levels of Gβ5 segregating into TX100-
soluble (white bars) and TX100-insoluble (black bars) biochemical fractions 
expressed as percentage of the total cellular Gβ5 signal from the respective 
cellular samples (mean ± SEM; n = 4, *p < 0.01, t-test relative to cells expressing 
Gβ5 alone.   
C.  Representative image of a Western blot depicting the segregation of the 
respective FLAG-tagged dopamine receptor proteins, D2R and D4R, into TX100-
soluble (S) and insoluble (I) biochemical fractions prepared from HEK293 cells 
transfected with the indicated cDNAs.   
D.  Quantification of the relative levels of D2R and D4R segregating into TX100-
soluble (white bars) and TX100-insoluble (black bars) biochemical fractions 
prepared from cell samples indicated in C (mean ± SEM; n = 4).   
E.  Representative image of a Western blot depicting the segregation into TX100-
soluble (S) and insoluble (I) biochemical fractions of Gβ1 protein transiently 
expressed in HEK293 cells and effect of transient coexpression of D2R on such 
segregation.   
35 
F.  Quantification of the relative levels of Gβ1 segregating into TX100-
soluble (white bars) and TX100-insoluble (black bars) biochemical fractions. 
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Fig. 2.  Coexpression of D2R enhances the expression of Gβ5 but not of Gβ1 
and coexpression of MOR does not significantly alter expression of Gβ5.   
A.  Representative images from a Western blot depicting the relative levels of 
expression of Gβ5 protein in HEK293 cells transfected with cDNA for the 
indicated proteins.   
B.  Quantification of the relative cellular expression levels of Gβ5 after 
coexpression of MOR or D2R.  The Gβ5 protein signal is expressed as a percent 
of the signal measured in cells expressing Gβ5 alone (mean ± SEM; n = 4, 
*p<0.05, ANOVA followed by Tukey’s post-hoc test, compared to the levels in 
cells expressing just Gβ5).   
C.  Representative images from a Western blot depicting the relative levels of 
expression of Gβ1 protein in HEK293 cells transfected with cDNA for the 
indicated proteins.   
D.  Quantification of the relative cellular expression levels of Gβ1 after 
coexpression of D2R.  The Gβ1 protein signal is expressed as a percent of the 
signal measured in cells expressing Gβ1 alone (mean ± SEM; n = 3, 
*p<0.05, t-test, compared to the levels in cells expressing just Gβ5). 
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Fig. 3.  Coexpression of D2R enhances the stability of Gβ5.   
A.  Representative image of a Western blot which depicts Gβ5 cellular 
expression levels, from HEK293 cells transiently expressing either Gβ5 alone or 
Gβ5 coexpressed with D2R, at times, t = 0, 3, or 6 hr after treatment with 
cycloheximide (100 µM).   
B.  Quantification of the reduction in cellular Gβ5 levels after treatment of cells 
with cycloheximide.  The Gβ5 levels at times 3 and 6 hr after cycloheximide 
treatment are expressed as a percentage of the levels of Gβ5 measured in cells 
that were not treated with cycloheximide (mean ± SEM; n = 4, *p<0.05, t-test, 
comparing to the cells that did not coexpress D2R). 
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Fig. 4.  Interactions of Gβ5 with TX100 soluble (S) and insoluble (I) D2R 
populations as assessed by an in-cell “proximity biotin transfer assay.” 
A.  Schematic of the Gβ5-BL construct, a fusion of Gβ5 with BirA, an E. coli 
derived biotin ligase (BL) enzyme that specifically biotinylates a unique acceptor 
peptide (AP) sequence (top panel).  N and C refer to the N- and C-terminus, 
respectively, of the fusion protein.  Schematic of KRAS-BL, a fusion of the BirA 
biotin ligase (BL) enzyme with the plasma membrane targeting peptide motif from 
KRAS (center panel).  Schematic of the D2R-AP fusion construct where the AP 
sequence that is specifically biotinylated by BirA was inserted into a region of the 
3rd cytoplasmic loop of FLAG-tagged D2R (bottom panel).   
B.  Representative image of a Western blot depicting the segregation, into 
TX100-soluble (S) and insoluble (I) HEK293 cellular fractions, of the D2R-AP 
construct that was biotinylated by either co-expressed Gβ5-BL or KRAS-BL.  The 
left and center panels represent samples prepared from HEK293 cells transiently 
coexpressing D2R and Gβ5-BL.  Samples in the left panel were from cells not 
treated with biotin (biotin −).  Samples depicted in the center panel were from 
cells transiently coexpressing D2R and KRAS-BL and samples depicted in the 
right panel were from cells transiently coexpressing D2R and Gβ-BL.  Cells were 
cultured in biotin-depleted medium and biotinylation of the D2R-AP construct by 
either Gβ5-BL or KRAS-BL was initiated in intact cells by treatment with 10 µM 
biotin for 2 min (biotin +).  Biotinylated D2R-AP segregating into TX100-
soluble (S) and insoluble (I) fractions was detected by probing the blots with 
streptavidin.   
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C.  Quantification of the percent of the biotinylated D2R-AP segregating into 
TX100-insoluble (I) and soluble (S) fractions after biotinylation by either 
KRAS-BL or Gβ5-BL (mean ± SEM; n = 4, *p<0.05, t-test, compared to the 
segregation after biotinylation by KRAS-BL).    
D.  Schematic of an explanation for the data presented in B and C.  The majority 
of the D2R-AP construct is expressed in plasma membrane domains that are 
TX100-insoluble (black filled-in region of the plasma membrane) but some 
D2R-AP is also expressed in a TX100-soluble form (white open region of the 
plasma membrane).  Gβ5-BL is able to access, interact with and biotinylate both 
forms with equal efficacy (lower panel).  The interactions of KRAS-BL, on the 
other hand, are largely restricted to the TX100-soluble form of D2R-AP indicated 
that it is compartmentalized away from the TX100-insoluble D2R-
AP (upper panel).     
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Fig. 5.  Effect of Gβ5 on dopamine-mediated activation of D2R-coupled G 
protein signaling as measured by a fast kinetic BRET assay.   
A.  Averaged traces (± SEM) of changes in the BRET signal (ΔBRET or the 
BRET response) over time obtained from HEK293 cells transfected with cDNA 
for D2R, Gαo, Venus-Gβγ, masGRK3ct-NanoLuc and treated sequentially with 
dopamine (10 nM) and haloperidol (100 µM).  D2R stimulation by dopamine 
application leads to the dissociation of the G protein heterotrimer into Gβγ-Venus 
and GTP-bound Gαo subunits.  Free Gβγ-Venus interacts with masGRK3ct-
NanoLuc to produce a BRET signal. The black trace is from HEK293 cells that 
did not coexpress Gβ5 and the dark and light grey traces are from HEK293 cells 
transiently coexpressing two different levels (l, for low and h, for high) of 
Gβ5 (mean ± SEM; n = 4).   
B.  Quantification of the amplitude of the BRET signal elicited by the application 
of sub-saturating dopamine concentration (10 nM) in the cells described above.   
C.  Quantification of the deactivation kinetics of the dopamine-elicited BRET 
response after application of the D2R antagonist, haloperidol (100 µM).   
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Fig. 6.  Effects of Gβ5 and Gβ1 coexpression on levels of cell surface D2R 
and MOR and on agonist-induced receptor internalization.   
A.  Quantification of the relative levels of cell surface D2R in HEK293 cells 
transiently transfected with a fixed amount of D2R cDNA and with cDNA for 
either Gβ1 or Gβ5.  The cell surface D2R signal is expressed as a percent of the 
signal measured in cells transfected with the only the fixed amount of D2R cDNA.  
The levels of D2R specifically at the cell surface was evaluated by probing intact, 
non-permeabilized cells with anti-FLAG antibody targeting the D2R-fused 
extracellular N-terminal FLAG tag (mean ± SEM; n = 8-16, *p<0.01, Tukey’s 
post-hoc test, compared to cells expressing D2R alone).   
B.  Quantification of the relative levels of cell surface MOR in HEK293 cells 
transiently transfected with a fixed amount of MOR cDNA and with cDNA for 
Gβ5. The cell surface MOR is expressed as a percent of the signal measured in 
cells transfected with only the fixed amount of MOR cDNA. The levels of MOR 
specifically at the cell surface were evaluated by probing intact, non-
permeabilized cells with anti-FLAG antibody targeting the MOR-fused 
extracellular N-terminal FLAG tag (mean ± SEM; n = 11-12). 
C.  Quantification of the relative levels of transiently expressed cell surface D2R 
in HEK293 cells expressing D2R alone, D2R and Gβ1 or D2R and Gβ5, after 
treatment of with dopamine (50 µM for 45 min).  The cell surface D2R signal is 
expressed as a percent of the signal measured in corresponding cells that were 
not treated with dopamine (mean ± SEM; n = 8, *p<0.01, t-test, compared to cell 
surface D2R signal from corresponding cells not treated with dopamine).   
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D.  Quantification of the relative levels of transiently expressed cell surface MOR 
in HEK293 cells expressing MOR alone and MOR with Gβ5, after treatment of 
DAMGO (50 µM for 45 min). The cell surface MOR signal is expressed as a 
percent of the signal measured in corresponding cells that were not treated with 
DAMGO (mean ± SEM; n = 11-12, *p<0.001, t-test, compared to cell surface 
MOR signal from corresponding cells not treated with DAMGO). 
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Fig. 7. Effect of Gβ5 coexpression on arrestin recruitment to D2R-AP upon 
dopamine treatment as assessed by an in-cell “proximity biotin transfer 
assay.” 
A.  Schematic of the Arr-BL construct, a fusion of arrestin and BirA, an E. coli 
derived biotin ligase (BL) enzyme that specifically biotinylates a unique acceptor 
peptide (AP) sequence.  N and C refer to the N- and C-terminus, respectively, of 
the fusion protein. 
B.  Representative images from a Western blot depicting total cellular 
biotinylated D2R-AP by coexpressed Arr-BL (top panels) and coexpressed 
Gβ5 (bottom panels).  The top left panel represents samples prepared from cells 
which were untransfected with either D2R-AP (−) or Arr-BL (−) and treated with 
10 µM biotin for 2 min (biotin +, left) or samples that were transfected with both 
D2R-AP (+) and Arr-BL (+) and not treated with biotin (biotin −, right).  The top 
center panel represents samples prepared from cells that were transfected with 
both D2R-AP (+) and Arr-BL (+) and treated with vehicle (dopamine −, left) or 10 
µM dopamine for 30 minutes (dopamine +, right) and treated with biotin. The top 
right panel represents samples prepared from cells that were transfected with 
both D2R-AP (+), Arr-BL (+), and Gβ5 (+) and treated with vehicle (dopamine −, 
left) or 10 µM dopamine for 30 minutes (dopamine +, right) and treated with 
biotin (+).  D2R-AP biotinylated by Arr-BL was detected by probing the blots with 
streptavidin. The bottom panels represent corresponding western blots from 
samples in the upper panel probed for Gβ5. 
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C.  Quantification of the relative levels of D2R-AP biotinylated by Arr-BL in 
response to dopamine treatment (10 µM for 30 min) in cells expressing only 
D2R-AP and Arr-BL or cells expressing D2R-AP, Arr-BL, and Gβ5.  The 
biotinylated D2R-AP signal is expressed as a percentage of biotinylated D2R-AP 
signal from cells that were not treated with dopamine (mean ± SEM; n = 4, 
*p<0.05, t-test, compared to biotinylated D2R-AP signal from corresponding cells 
not treated with dopamine). 
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ABSTRACT 
It is thought that all available antipsychotic drugs can reduce psychotic symptoms 
by blocking D2R at therapeutic concentrations; however it is unclear how the 
blockade of D2R is sufficient to produce these effects.  Previously we have 
demonstrated that D2R exists predominantly in a detergent insoluble and 
compartmentalized biochemical fraction and that insoluble D2R at the plasma 
membrane is internalized in response to dopamine.  To determine if 
antipsychotics produced changes to the receptor’s compartmentalization 
characteristics we examined the effects of numerous antipsychotic drugs on the 
biochemical properties of D2R in vitro.  We found that all antipsychotics tested 
significantly enhanced the surface localization, as well as enhancing the solubility 
of D2R, without producing changes on the overall expression of the receptor in 
our system. The one drug that did not produce changes in the solubility of D2R 
was clozapine, an antipsychotic agent thought to be particularly effective in 
treatment-resistant schizophrenia.  We found that these changes in surface 
receptor expression levels resulted in enhanced accessibility of D2R, as 
measured by a proximity dependent, biotin-transfer assay, in both a dose and 
time-dependent fashion. Among the drugs we tested, haloperidol uniquely 
enhanced the accessibility of detergent insoluble D2R and this effect was 
blocked by saturating concentrations of clozapine.  
Keywords: Antipsychotics, Detergent resistant membrane compartments, G 
protein coupled receptor, D2-dopamine receptor, Plasma membrane 
compartmentalization, Mechanism of action 
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Abbreviations: ANOVA, analysis of variance; AP, attenuated acceptor peptide 
with the sequence GLNDIFEAQKIE; βMCD, β-methylcyclodextrin; cDNA, 
complementary DNA; DRM, detergent resistant membrane; EPS, extrapyramidal 
symptoms; GPCR, G-protein coupled receptor; HEK293, human embryonic 
kidney cells stably expressing the SV40 T-antigen; HRP, horseradish peroxidase; 
KRAS-BL, BirA biotin-ligase fusion construct with the membrane-targeting 
domain with the sequence KKKKKKSKTKCVIM from the protein KRAS; PET, 
positron emission tomography; TCA, trichloroacetic acid; TX100, Triton X-100; 
V5, V5 epitope tag with the amino acid sequence GKPIPNPLLGLDST; 
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INTRODUCTION 
Schizophrenia is an intractable and debilitating chronic mental disorder known to 
affect approximately 1% of the population. Antagonists of the D2-like family of 
dopamine receptors (antipsychotics) are used in the treatment of the 
hallucinations and delusions that are the so-called the “positive” symptoms of 
schizophrenia. Specifically the D2 dopamine receptor (D2R) is a clinically 
important G coupled receptor (GPCR), as it serves as the major target of drugs 
used to treat a variety of mental disorders such as Parkinson’s disease, 
depression and schizophrenia (1, 2). 
A common property of all available antipsychotic drugs is that they specifically 
block the D2 dopamine receptor (D2R) at therapeutic concentrations (3). Also, it 
has been demonstrated that the clinical potency of the first generation or “typical” 
antipsychotics is directly correlated with their relative affinities for D2-like 
dopamine receptors (Hartman, 1996). From these data it is evident that 
antipsychotic drugs necessarily block D2R to produce reduction of psychotic 
symptoms, however it is still unclear how antipsychotic induced blockade of D2R 
is sufficient to produce this effect. 
In this report we demonstrate that all antipsychotics tested in this study can 
decrease the segregation of D2R into detergent resistant membrane structures 
(DRMs) and enhance in the accessibility of DRM localized D2R to other cellular 
proteins, as measured by a novel biotinylation assay. It is this consistent 
alteration between antipsychotics that represents a model for antipsychotic drug 
actions and a potential target for the development of antipsychotic drugs that are 
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more directly effective in accomplishing a complete reduction of positive 
schizophrenic symptoms. 
In several large, multi-site randomized controlled-trial studies of the effectiveness 
of antipsychotic drugs it was determined that there existed little or no differences 
between the newer atypical and conventional typical antipsychotic drugs(16, 17). 
Unique among these antipsychotic agents, was the drug clozapine that was 
found to be efficacious for applications in treatment resistant schizophrenia. 
Fundamental to our understanding of the classical mechanism of antipsychotic 
drug action is that antipsychotics block of the native ligand dopamine from 
binding to D2R that leads to the prevention of downstream signaling. However, 
with notable few exceptions, complete occupancy of D2R, by antipsychotics in 
the brain is sufficient to produce serious extrapyramidal side (EPS) effects and 
therefore demonstrates the need to titrate doses accordingly to produce a 
consistent reduction in schizophrenic symptoms (7). Interestingly even when 
sufficiently high doses of the atypical agent quetiapine were used to produce 
clinically significant reduction of schizophrenic symptoms, receptor occupancy 
was significantly lower than the “therapeutic window” (8). It therefore seems 
unlikely that simple measures of receptor occupancy are conclusive in 
determining antipsychotic efficacy. 
The difference in effectiveness of suppression of psychotic symptoms in 
schizophrenia seen with the newer atypical antipsychotics might be due to their 
decreased binding affinity of D2R (9, 10).  Differences between the binding 
affinities of atypical and typical antipsychotics are almost entirely (~99%) due to 
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the relative differences in the dissociation constant. The enhanced dissociation of 
antipsychotic from receptor is proposed to enable endogenous dopamine to 
continue to signal via D2Rs, despite receptor blockade, and may be involved in 
the reduction of extrapyramidal symptoms in the atypical antipsychotics. Yet, the 
difference between the relative binding affinities of typical and atypical drugs 
does not explain the unique effectiveness of clozapine in producing a reduction in 
treatment-resistant schizophrenic symptoms. 
Previous studies on the antipsychotic interaction with D2R have measured 
ligand-binding properties using receptor radioactive assay or PET imaging (7, 8, 
9). Although these types of studies can describe quantitative changes in 
receptor-ligand affinities, these techniques do not specifically describe the 
underlying molecular consequences of the interaction between antagonists and 
D2R on the ability of the receptor to signal. Most notably, neither of these 
methods can ask how different biochemical properties of specific pools of D2R 
within the same cell can contribute to signaling. 
We have previously demonstrated that compared to other GPCRs, D2 dopamine 
receptors are preferentially localized in detergent resistant membrane structures 
(DRMs) in the plasma membrane and coexpression of D2R can alter the 
detergent solubility of important members of the D2 signaling cascade such as 
RGS9-2 (11). Additionally we have identified that the compartmentalization of 
D2Rs within these detergent resistant plasma membrane structures functionally 
limits the accessibility of D2R to other plasma membrane associated proteins 
(13). Together these discoveries suggest that not only does the majority of 
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cellular exist in a membrane fraction that is resistant to detergent solubilization, 
but also that this fraction specifically allows for the compartmentalization of D2R 
and its associated signal transducers. Therefore, drugs that are able to alter the 
relative compartmentalization of D2R into or out of DRMs could potentially alter 
its signaling characteristics. 
Here we demonstrate a unique effect of antipsychotics on not only the 
distribution of D2Rs between detergent resistant membranes and detergent 
soluble partitions, but also a change in the potential signaling characteristics of 
both fractions of the receptor. Initially we show that D2Rs enhance the relative 
amount of D2R found in the detergent soluble fraction. Additionally, we used a 
previously described biotin ligase mediated in-cell biotin transfer assay, to 
demonstrate that antipsychotic enhances the accessibility of D2R in both 
detergent soluble and insoluble fractions to membrane bound proteins. 
Furthermore, by correcting for the relative protein found within each membrane 
fraction we found that haloperidol preferentially enhanced the efficacy of 
biotinylation of detergent insoluble targeted D2Rs. Critically these effects 
represent novel effects of drug on receptors and their function and therefore add 
a significant dimension to the understanding of antipsychotic drugs mechanisms 
of action at D2R.  
MATERIALS AND METHODS 
Chemicals 
Ziprasidone hydrochloride monohydrate, olanzapine, quetiapine hemifumarate 
salt, fluphenazine dihydrochloride, resperidone, (S)-(-) sulpiride, and droperidol 
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were acquired from Sigma- Aldrich (St. Louis, MO, USA). Haloperidol and 
clozapine were acquired from MP Biomedicals LLC (Solon, OH, USA). 
Aripiprazole was acquired from AK Scientific (Union City, CA, USA).  All other 
chemicals and reagents were purchased from Fisher Scientific (Pittsburg, PA, 
USA) or from other suppliers specifically identified below. 
Cell Culture and Transfection 
HEK293 cells(American Type Culture Collection, Manassas, VA, USA) were 
maintained and transfected in Dulbecco’s modified Eagle’s medium with 10% 
fetal bovine serum (company) plus penicillin/streptomycin. The cells were grown 
at 370C and 5%CO2. Transfection of HEK293T cells was carried out using 
Lipofectamine LTX(Invitrogen) according to manufacturer’s instructions. Total 
transfected DNA was kept constant between groups using the empty vector 
pcDNA 3.1+/zeo  (Invitrogen)    
cDNA Constructs 
All plasmid constructs utilized below were designed and made using standard 
techniques in molecular biology.  The N-terminal FLAG-tagged version of the 
human D2-dopamine receptor (D2R) (12), the FLAG-tagged D2R construct with 
the biotin ligase acceptor peptide insertion into the 3rd cytoplasmic 
loop (D2R-AP), the BirA biotin ligase fusion construct with the plasma membrane 
targeting domain of Lyn kinase (LYN-BL), and the BirA biotin-ligase fusion 
construct with the membrane targeting domain of KRAS (KRAS-BL) (13) have 
previously been described.  The D2R-AP construct consists of the FLAG-tagged 
D2R into which an attenuated acceptor peptide sequence (GLNDIFEAQKIE) is 
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inserted between amino acids at position 305 and 306 in the 3rd cytoplasmic 
loop.  LYN-BL consisted of the following fused peptide sequences, in order, from 
the N to the C-terminus: a membrane targeting peptide sequence 
(MGCIKSKRKDNLNDDE) from Lyn kinase, the GSGSG linker, BirA and the V5 
epitope-tag.  KRAS-BL consisted of the following peptide sequences in order 
from the N to the C-terminus: the V5 epitope-tag, BirA biotin ligase enzyme (BL), 
a GSGSG linker and a membrane targeting peptide sequence 
(KKKKKKSKTKCVIM) from the protein KRAS.  
TX100 Biochemical Fractionation of Proteins 
The method for the Triton X-100 (TX100) biochemical fractionation of proteins 
has been adapted from previous publications (11, 13).  Briefly, 48 hr post 
transfection cells were lysed in phosphate-buffered saline (PBS, in mM: 137 
NaCl, 2.7 KCl, 10 Na2HPO4, 2 KH2PO4, pH 7.4) containing 2% v/v of the non-
ionic detergent, TX100 and a 1× concentration of SigmaFast Protease 
inhibitor (Sigma-Aldrich) for 1 hr at 4 ºC. The samples were 
centrifuged (10,000 g, 10 min at 4 ºC) to pellet the insoluble proteins.  
Supernatant proteins (i.e. the TX100-soluble fraction) were precipitated by the 
addition of trichloroacetic acid (TCA, final concentration 10% v/v).  Supernatant 
proteins were washed 3× with ice-cold 95% v/v acetone (4 °C).  Both the TX100-
soluble and the insoluble proteins were re-suspended in equal volumes of SDS 
sample buffer (2% w/v SDS, 0.01% w/v bromophenol blue, 8 M urea, 
20 mM dithiothreitol, 50 mM Tris-HCl, pH 6.8).  Samples were sonicated, on ice, 
25× for approximately 0.5 seconds at power setting of 10 for ~0.5 s to reduce 
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sample viscosity prior to loading using a sonicator (XL-2000, qSonica).  Equal 
volumes of the samples were then resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and the relative levels of protein 
expression were then compared by Western blotting. 
In-Cell Biotin Transfer Assay 
We utilized an in cell biotin transfer assay to detect whether or not KRAS-BL 
interacted with detergent soluble or insoluble forms of D2R.  On day one 
approximately 2.5 × 105 cells were transfected in a 2:1 ratio with plasmid DNA 
containing KRAS-BL and D2R-AP Lipofectamine transfection reagent (Invitrogen) 
according to manufacturer’s instructions, in biotin free media. 24 hours post 
transfection cells were incubated with an appropriate concentration of an 
antipsychotic drug. At 48 hours post-transfection or 24 hours post drug 
application, cells were treated with a 40 µM biotin pulse for 5 minutes and placed 
back into the incubator. Cells were then harvested from the plate using a 
micropipette and washed 3 times with cold 1x PBS. Cell samples were 
solubilized in ice-cold phosphate buffered saline containing 2% TX-100 and 
protease inhibitors for an hour. After an hour samples were centrifuged at 10,000 
g for 10 minutes. Supernatant was decanted by micropipette into a separate tube 
and precipitated by the addition of 10% Trichloroacetic acid. Soluble and 
insoluble proteins were then harvested using the method as described in the 
“Triton X-100 Biochemical Fractionation of Proteins” section. 
Samples were then resolved by SDS PAGE. The proteins were then transferred 
to methanol-wetted polyvinylidene fluoride (PVDF) membranes and probed with 
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streptavidin conjugated to horseradish peroxidase (HRP).  These procedures and 
reagents are described in the “Protein Immunoblotting” section below.   
Detection of Total Surface Expression of D2R-AP 
To determine the effect of antipsychotic drugs on receptor surface expression we 
used an ELISA-based assay to determine the amount of receptor present at the 
plasma membrane. Day 1, 5 × 104 HEK293 cells were transfected with 
appropriate cDNA plasmids containing D2R-AP in a 96-well plate.  36 hours post-
transfection cells were treated with a saturating concentration (10 µM) of the 
indicated antipsychotic drug for  24 hours.  The media was then aspirated, and 
cells were gently washed 3 times with cold (4 °C) PBS.  Cells were then fixed 
with 4% v/v  formaldehyde in PBS, and then washed 3 times with PBS.  Wells 
were blocked for 30 minutes with 5% nonfat milk dissolved in PBS.  Surface 
receptor was then probed for using HRP-conjugated mouse monoclonal anti-
FLAG M2 antibody (1:5,000 dilution in 5% nonfat milk in PBS, Sigma) for 1 hour 
at 37 °C and then washed 3 × with PBS.  Supersignal West Femto 
chemiluminescent substrate (Pierce-Thermo Fisher Scientific) was then applied 
to each well and signals were detected and quantified using a multi-well plate 
compatible luminometer (Glomax) and attached computer. 
Indirect Detection of TX100 Soluble and Insoluble Cell Surface D2R-AP 
HEK293T cells were transiently transfected with cDNA for FLAG tagged D2R-AP 
or with the empty vector. The intact cells were then incubated in cell-culture 
medium with antibody (Sigma Aldrich; clone M2, catalog no. F1804, 1 : 500 
dilution) directed against the extracellular FLAG-tag for 1 h at 37°C to label the 
63 
respective surface receptors. The cells were then washed three times in ice-cold 
PBS (5 min, 4°C, incubation in PBS for each wash). TX100-soluble and -
insoluble proteins were isolated, resolved on SDS–PAGE and western-blotted as 
described below. The anti-FLAG antibody light chain that labeled the surface 
receptors and co-fractionated into the TX100-soluble and -insoluble 
compartments was visualized by detection using a anti-murine HRP-conjugated 
secondary antibody (Jackson ImmunoResearch Laboratories). 
Protein Immunoblotting  
Protein samples, prepared as described above, were resolved by SDS-PAGE 
and transferred, using wet electrophoretic elution buffer (25mM Tris-base, 
192mM glycine, 20% v/v methanol, 0.1% w/v SDS, pH~8.3), and subsequently 
transferred onto methanol-wetted polyvinylidene fluoride (PVDF) membranes. 
After blocking remaining protein-binding sites with 5% w/v nonfat milk powder in 
PBS, the proteins of interest were detected by probing the blots sequentially with 
the appropriate primary and HRP conjugated secondary antibodies, diluted in 5% 
w/v nonfat milk and PBS. For Streptavidin blotting, the membrane was incubated 
with streptavidin-HRP (Sigma, 1:5000 in 3% BSA, PBS) for 1 hr, followed by four 
10 min washes in PBS. For anti-V5 blotting, the membrane was incubated with 
Anti-V5 HRP (Invitrogen, 1:5000 in 3% BSA, PBS) for 1hour, then washed by 
four 10 min washes in PBS. In order to detect Flag-D2R or D2R-AP signal , the 
membrane was incubated with anti-FLAG antibody (Sigma-Aldrich) for 1 hr, 
followed by three 10 min washing with PBS. For the detection of total cellular 
protein segregating into TX100 soluble and insoluble biochemical fractions, after 
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HRP-based detection, PVDF membranes were incubated in Coomassie stain 
(40% methanol, 1% acetic acid, 0.1% brilliant blue R-250 dye) and washed 3× for 
10 minutes each with Coomassie wash buffer (50% methanol, 1% acetic acid). 
For HRP conjugated antibodies, blots were developed with Supersignal West 
Femto substrate (Pierce), and images were taken on the Chemiluminescence 
setting on Bio Rad Gel Doc XRS. The intensity of each band was quantified 
using Image J software.  Images were taken using exposure settings that did not 
saturate any of the charge-coupled device camera pixels. 
Data and Statistical Analysis 
Signals from the target protein bands were quantified using the free image 
processing and analysis software ImageJ (National Institutes of Health, 
Bethesda, MD, http://rsbweb.nih.gov/ij/).  Statistical analyses were performed 
using Microsoft Excel or GraphPad Prism 4 software (GraphPad Software, Inc.).  
The signals resulting from detergent-soluble and insoluble preparations of a 
protein, respectively, were expressed as a fraction of the total signal per sample 
of cells or in cases specifically indicated as a fraction of vehicle in the 
corresponding (T100 soluble or insoluble) sample. When testing the significance 
of means for more than 2 experimental groups, one-way ANOVA was used to 
first determine group statistical significance and only followed by either Dunnett’s 
post-hoc test, for determination of mean difference from vehicle treated controls 
or Tukey’s post-hoc analysis if comparing between multiple different treatment 
conditions. Post-hoc analyses were performed only if the results of the initial 
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ANOVA were determined to be significant (p<0.05). 
RESULTS 
All antipsychotic drugs tested enhanced the detergent solubility of total cellular 
D2R-AP without enhancing expression of D2R-AP, with the exception of 
clozapine. 
Previously we have shown that D2R expressed in the brain or exogenously in 
HEK293 cells  exists predominantly within a fraction of the plasma membrane 
that is insoluble in nonionic detergent and D2R retargets proteins to these 
biochemical fractions (11, 13). Furthermore we have demonstrated that these 
insoluble biochemical fractions respond to dopamine treatment by reducing 
available cell surface D2R within this fraction, likely through internalization (13). 
Therefore we asked whether or not alternative D2R binding ligands produce 
changes in the accessibility of either (soluble or insoluble) pool of D2R.   
24 hour, saturating concentrations of antipsychotics appeared to specifically 
enhance the pool of soluble D2R-AP (Fig. 1B). The exception to this statement 
was the antipsychotic drug, clozapine, which showed no difference from vehicle 
treated cells, in terms of solubility of all cellular D2R-AP.  Furthermore, 
antipsychotics did not uniformly enhance the expression of total D2R-AP under 
these treatment conditions (Fig. 1C). Rather, it appeared that two drugs, 
resperidone and aripiprazole, decreased the overall expression of the D2R-AP 
construct. 
We have previously demonstrated that the insoluble pool of receptor is 
functionally segregated at the plasma membrane (13). Therefore it may be that 
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antipsychotics that enhance the soluble fraction of cellular D2R thereby disrupt 
targeting to insoluble biochemical fraction.  It is likely that through an alteration in 
the targeting of D2R to different compartments in the plasma membrane alters 
the ability of D2R to signal once it has reached this compartment. 
Antipsychotic drugs enhanced surface translocation of D2R-AP as measured by 
modified ELISA assay 
To compare the relative abilities of these antipsychotics to enhance the surface 
receptor concentrations we transiently expressed only D2R-AP in 96-well plates 
and treated these cells with a 10µM concentration of antipsychotic for 24 hours. 
We found that after this treatment, total surface receptors were significantly 
increased from 1.7 to approximately 5 fold after the drug treatment (Fig. 2). 
Haloperidol and clozapine enhance surface translocation of D2R-AP, but do not 
increase detergent solubility of surface D2R-AP.  
In order to examine whether or not the effect of antipsychotics on the solubility of 
total cellular D2R-AP was also conferred to surface receptors we examined the 
solubility of surface receptors after antipsychotic treatment using an indirect 
detection method summarized in figure 3A. Although haloperidol and clozapine 
both robustly enhanced the total amounts of cell surface receptors (Fig. 3D), we 
found that the relative solubility of the surface receptors was unchanged 
compared to vehicle treated cells (Fig. 3C).  A summary of this effect is provided 
in figure 9A. 
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Certain antipsychotic drugs enhance the accessibility of D2R-AP to interactions 
occurring at the plasma membrane. 
To assess the potential for changes in the cell signaling of D2R upon 
antipsychotic drug treatment we used an in-cell, proximity-dependent, biotin 
transfer assay that involves the E. coli biotin ligase (BL). Biotinylation of D2R-AP, 
which occurs within 5 minutes prior to cell lysis, is further evidence of an 
interaction that has occurred in living cells (14, 15). 
To assess if antipsychotics could disrupt the compartmentalization of D2R-AP at 
the plasma membrane, we used an in-cell proximity dependent biotinylation, a 
diagram of the proximity dependent biotinylation assay is provided in figure 4. 
The effect of antipsychotics on the accessibility of cell surface D2R is likely due 
to the increased receptors levels that were observed in figure 2. 
Several antipsychotics enhance the accessibility of cell surface D2R-AP as 
measured by in-cell proximity dependent biotinylation assay, however haloperidol 
most robustly enhances accessibility of insoluble pools of receptor (fig. 5B).  
Haloperidol treatment alters the biochemical fractionation of biotinylated D2R-AP, 
by enhancing soluble fraction of biotinylated D2R-AP (Fig. 5C). Additionally, 
haloperidol most robustly enhanced insoluble biotinylated D2R-AP (Fig 5D) and 
robustly enhanced the biotinylation of D2R-AP only after 4 hours of treatment 
(Fig 7B).  However, there was no effect observed in the biotinylation of soluble 
D2R-AP at 4 hours (Fig. 7C). 
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Biotinylation in the insoluble pool of receptor increased more dramatically with 
haloperidol treatment, approximately 8 fold, than those of soluble receptors, 
which differed from vehicle by only ~3 fold (Fig. 6C and D). 
Haloperidol’s effect on insoluble D2R-AP compartmentalization is blocked by the 
drug clozapine. 
To determine if the effect of haloperidol was specific to the interaction of 
haloperidol with the receptor and not through a non-specific interaction, we 
treated D2R-AP expressing cells with a 1µM concentration of haloperidol and 
found an increase in biotinylation of D2R-AP in both soluble and insoluble 
fractions (Fig. 8B) which was consistent with our previously observed results in 
figures 6C and D. A similar strategy was originally used in the discover of D2-
dopamine receptors, which used other antipsychotic drugs could block tritiated 
haloperidol from interaction with brain tissue (16, 17). A diagrammatic 
representation of the results obtained of decreased insoluble D2R-AP 
compartmentalization is provided in figure 9B. 
DISCUSSION 
Unique responses of plasma membrane and intracellular D2R to antipsychotic 
treatment 
Understanding the way D2R functions under antipsychotic blockade is crucial to 
the future development of safer and more effective of antipsychotic drugs. 
Generally, greater than 50% of receptors are bound by antipsychotic drugs for 
therapeutically effective concentration of these agents (18). Because of a wide 
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difference in the relative affinity of antipsychotics for D2R (e.g. approximately 225 
fold difference in binding constant of droperidol relative to quetiapine) we used 
saturating (10µM) concentrations of all antipsychotics to study their function on 
the receptor (30). 
Previously we demonstrated that both detergent insoluble form and soluble forms 
of D2R exist within the plasma membrane (13).  Insoluble D2R has recently been 
shown to exhibit the property of plasma membrane compartmentalization in 
HEK293 cells (13). Whereas, the detergent soluble form of D2R is likely to 
originate from a fluid region of the cell membrane that does not functionally 
restrict the access of D2R to other signaling molecules (19).  We found that 1) all 
antipsychotics enhanced the accessibility of cell surface receptors and 2) the 
majority of antipsychotics enhanced the solubility of total cellular receptors. 
Importantly, the total solubility of D2R is not representative of surface D2R 
solubility, as evidenced by the observation that when we examined the solubility 
of cell surface receptors, we found that haloperidol did not enhance the fraction 
of soluble receptors compared to vehicle.  It is possible that D2R exhibits 
undiscovered intracellular roles in addition to the signaling, as there are 
significant pools of intracellular D2R in striatal neurons and in transfected cell 
lines (20). 
Previously it has been shown that alternative signaling via arrestin may occur in 
endosomal targeted pools of adrenoreceptors (21).  Furthermore, internalization 
processes mediated through arrestin may activate a number of non-G-protein 
mediated signal transduction mechanisms that may yet be undescribed (22). 
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Therefore it is unlikely that the only physiologically important forms of the 
receptor are those that are targeted to the cellular plasma membrane. 
Changes in receptor compartmentalization mediated by antipsychotics is unlikely 
to be mediated through to lipid-drug interactions. 
It is a common assumption that the therapeutic actions of antipsychotic drugs 
results form the antagonistic activity of the drug in binding and blocking D2R from 
interacting with dopamine. It has been demonstrated that haloperidol can 
produce changes in model membranes of lipid bilayers (23). Therefore it was 
hypothesized that the actions of antipsychotics within biological membranes may 
be to enhance the fluidity of the cell membrane. Our finding that haloperidol 
seems to disrupt the compartmentalization of insoluble forms of D2R-AP, seems 
to fit with this hypothesis. 
This hypothesis was recently revisited and demonstrated that antipsychotics can 
produce different changes in lipid-ordered domains in model membranes, 
through disruption of proteins within lipid raft structures; there is no evidence that 
D2R currently exists in such a cholesterol dependent membrane domain (13, 19–
21). If disruption of the plasma membrane compartments was simply a function 
of drug concentration in the bilayer, then we should see an additive effect of 
antipsychotics in enhancing plasma membrane fluidity, as measured with our 
proximity biotinylation assay. Our experiments showing that 1µM haloperidol, 
which exhibits high enhancement of D2R-AP fluidity, can be effectively competed 
off of it’s target by 100µM clozapine, which exhibits significantly lower 
enhancement of D2R-AP fluidity.  
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There are chemical agents that have been used to disrupt theoretical plasma 
membrane compartments, such as β-methylcyclodextrin (βMCD). βMCD is a 
widely used to chelate cholesterol that are thought to disrupts plasma membrane 
lipid raft compartments, through sequestration of cholesterol (24).  However 
haloperidol’s disruption of insoluble D2R compartments, is unlikely to occur 
through a non-specific disruption of detergent insoluble pools because 1) surface 
D2R is not made more soluble upon administration of the antipsychotic drug 
haloperidol and the 2) effect of increasing biotinylation of soluble D2R-AP is 
blocked through the co-administration of the drug clozapine.  
Altered D2R compartmentalization likely produces changes in receptor signaling 
In general, the effect of antipsychotic drugs in increasing the total biotinylation of 
D2R-AP was likely mediated through a similar process as the total enhancement 
of cell surface D2R-AP because these two results tended to correlate well.  
However, we found haloperidol uniquely disrupts the plasma membrane 
compartmentalization of insoluble D2R-AP, at the cell surface.  
Signaling mediated by the D2R-dopamine complex involves the G protein 
activation that suppresses the formation of cAMP, though gαi-mediated inhibition 
of adenylate cyclase.  As an enzymatic reaction, the rate of activation of G 
proteins is dependent on both those molecules’ concentration and proximity. 
Spatial restriction limits the local concentration of signaling molecules and can 
enhance the local cellular concentration of signaling molecules that could be 
diminished in their global cellular concentration. Therefore, by enhancing the 
accessibility of insoluble D2R to plasma membrane molecules, the unique 
72 
capacity of restricted-access, plasma membrane targeted D2R to limit signaling 
to certain molecules has been disrupted. 
On the other hand, most antipsychotics do not change the accessible fraction of 
cell surface receptor and this change does not appear to alter the ability of 
receptors at the cell surface to interact with membrane-targeted molecules. 
Rather, antipsychotic induced plasma membrane targeted receptors exhibit 
similar potential signaling properties to receptors that were integrated in the 
plasma membrane prior to antipsychotic treatment; i.e. there was minimal 
difference between total receptor interactions normalized per unit of receptor 
between drugs. Therefore, by virtue of enhanced surface expression and altered 
solubility, antipsychotic binding may produce actions of D2R on yet undefined 
pathways and not on classically defined interactions with G proteins and ion 
channels (25). 
Although a number of authors have suggested moieties within D2R that reduce 
the relative affinity of haloperidol or other antipsychotic drugs for D2R, at the time 
of publication, no mutation construct has been shown to demonstrate selectivity 
of drug-receptor interaction (26–29). Furthermore, by significantly disrupting the 
largely hydrophobic binding pocket of D2R, this process may produce receptors 
that lack proper folding or membrane targeting. 
Antipsychotic actions of clozapine may be related an ability to maintain a large 
intracellular pool of insoluble D2R. 
Although binding of the dopamine D2 receptor has been shown to be directly 
correlated to the therapeutic action of antipsychotic drugs, it is unclear how 
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antagonistic blockade of D2R relates to the therapeutic effectiveness (16, 30). 
We have shown here that antipsychotic drugs all seem to enhance the surface 
translocation of D2R-AP, through a mechanism independent of total expression 
of receptor. This result fits with the well-documented ability of antipsychotic 
agents to antagonize D2R arrestin recruitment and internalization (31–33). 
However, it appears that most of the antipsychotics we tested also demonstrate 
an ability to enhance the soluble fraction of D2R, through an undocumented 
process. The exception to this finding was the drug clozapine, an agent that is 
uniquely efficacious at reducing the psychotic symptoms of treatment resistant 
schizophrenia (34). 
Previously Seeman et al. demonstrated that antipsychotic drug potencies directly 
correlated with their relative binding affinities to D2R. Interestingly, clozapine, a 
drug with lowered incidence of movement disorder side effects also fits this 
correlation. Therefore it is likely that clozapine mediates its antipsychotic 
therapeutic action through binding to D2R (16, 17). The  reason why certain the 
atypical antipsychotics possess this lower liability might be due to a rapid 
dissociation of the drug from the D2R.  However recently it has been shown that, 
at least in electrophysiology experiments with the Xenopus laevis oocyte system, 
that most antipsychotic do not fully dissociate from their target receptor, even 
after extended washing (35, 36).  
The data we present here implicates the solubility of total cellular receptor as a 
potential therapeutic target for the development of antipsychotics that exhibit 
similar properties to clozapine. 
74 
Conclusions 
D2R is a receptor with numerous physiological functions that is implicated in the 
pharmacotherapy of a number of diseases, notably Parkinson’s disease and 
schizophrenia. Although it is more than 60 years since the discovery of the first 
antipsychotic agent, their exact mechanism of action remains to be elucidated. 
Here we show that antipsychotics can produce changes in the biochemical 
characteristics of D2R and that these changes are likely mediated through direct 
binding to D2R.  It may be that antipsychotics produce changes in cell signaling 
through directly blocking the interaction of D2R and dopamine, but the effects of 
antipsychotics on receptor compartmentalization remain an intriguing possibility 
for the future development of more efficacious agents.  Critical to our 
understanding of D2R function is the further elucidation of compartmentalized, 
non-compartmentalized, and intracellular forms of D2R-AP. 
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Fig. 1.  TX100 solubility of total cellular D2R under various antipsychotic drug 
treatments. 
A.  Representative image of a western blot depicting the distribution of D2R-AP 
protein in TX100-soluble (S) and insoluble (I) biochemical fractions. Fractions 
correspond to proteins extracted from transiently transfected HEK293 cells, 
treated with the indicated antipsychotic drug. 
B.  Quantification of the relative levels of D2R-AP protein segregating into TX100 
soluble and insoluble biochemical fractions prepared from transiently transfected 
HEK293 cells. Bars represent average soluble D2R-AP, expressed as a 
percentage of total cellular D2R-AP in each sample (mean ± SEM, n= 4-13; † 
indicates p<0.01 significantly different from vehicle soluble D2R-AP; ANOVA 
followed by Dunnett’s post-hoc test). 
C.  Quantification of the total cellular levels of D2R-AP expressed in transiently 
transfected HEK293 cells that were treated with the indicated antipsychotics. The 
total cellular D2R-AP is expressed as a percentage of the D2R-AP specific signal 
that was measured in corresponding wells that were treated with vehicle (mean ± 
SEM, n= 4-13; † indicates p<0.01 significantly different from vehicle total D2R-
AP; ANOVA followed by Dunnett’s post-hoc test). 
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Fig. 2.  Antipsychotic drug treatment enhances total surface expression of 
D2R as measured by modified ELISA. 
HEK293 cells were transiently transfected with plasmid containing the cDNA for 
D2R. 36 hours post-transfection cells were treated with a10µM concentration of 
the antipsychotic drug indicated. 24 hours post-drug treatment cells were then 
fixed and cell surface receptors were detected using an HRP-conjugated 
antibody directed against a FLAG epitope at the N-terminus of D2R. Bars 
represent average receptor signal from wells treated with the indicated 
antipsychotic drug expressed as a percentage of signal from vehicle treated wells 
(mean ± SEM, n= 15-16; * indicates p<0.05, † indicates p<0.01 significantly 
different from vehicle treated cells; ANOVA followed by Dunnett’s post-hoc test). 
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Fig. 3. TX100 solubility of cell surface D2R is unchanged with haloperidol 
or clozapine, as measured by indirect detection of D2R. 
A.  Diagrammatic representation of the receptor detected by co-
immunoprecipitation with the monoclonal anti-FLAG antibody. HEK293 cells 
transiently expressing D2R-AP were pre-treated with haloperidol, clozapine or 
vehicle.  After drug treatment, cells were incubated with anti-FLAG antibody and 
then lysed in buffer containing TX100.  After lysis, soluble and insoluble 
biochemical fractions were resolved by SDS-PAGE and an anti-murine antibody 
was used to detect anti-FLAG antibody light chain. 
B.  Upper panels: Representative images of a western blot depicting the 
distribution of anti-FLAG antibody light chain in TX100 soluble (S) and insoluble 
(I) biochemical fractions, from cells transiently transfected with D2R-AP and 
treated with the indicated antipsychotic drug or vehicle. CTRL treated cells were 
transfected with plasmid containing cDNAs for D2R-AP but not treated with the 
anti-FLAG antibody.  Lower panels: Representative images of a western blot 
depicting the distribution of total cellular proteins. Lanes in the lower panel are 
treated in the same manner as those in the corresponding lanes of the images of 
the upper panel. 
C.  Quantification of the relative levels of surface D2R-AP segregating into 
TX100 soluble (S) and insoluble (I) biochemical fractions. Bars represent 
average percentage of the surface D2R-AP per sample of treated cells as 
determined by indirect detection of cell surface receptor (mean ± SEM, n= 5-8). 
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D.  Quantification of the total levels of anti-FLAG antibody from transiently 
transfected HEK293 cells treated with the indicated antipsychotic or vehicle. Bars 
represent total surface receptor detected by the anti-FLAG antibody expressed 
as a percentage of vehicle treated cells (mean ± SEM, n= 4-7; * indicates p<0.05, 
† indicates p<0.01 significant difference between the bars indicated; ANOVA 
followed by Tukey’s post-hoc test). 
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Fig. 4.  Representative diagram of D2R-AP and KRAS-BL constructs in 
in-cell “proximity biotin transfer assay.” 
An in-cell proximity biotin transfer or biotinylation assay was utilized to detect 
D2R-AP, a D2-dopamine receptor construct with an acceptor peptide in the third 
intracellular loop, which interacted with KRAS-BL, a BirA, biotin ligase enzyme 
fused with the membrane targeting peptide from the protein KRAS. Upon 
cotransfection of plasmid containing cDNAs that code for each of these proteins 
some fraction of these transiently expressed proteins are inserted into the 
plasma membrane (top panel). Upon treatment of cells containing these proteins, 
KRAS-BL is able to covalently transfer a biotin to the AP region of D2R-AP, but 
predominantly soluble D2R-AP (white shaded region) and lesser of the insoluble 
D2R-AP, in the black shaded region (middle panel). Pre-treatment of cells 
containing these proteins with certain antipsychotic agents may cause changes 
in the accessibility of the plasma membrane targeted receptors to biotinylation 
(bottom panel). 
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Fig. 5.  Effect of antipsychotic drugs on plasma membrane accessibility of 
D2R-AP as assessed by an in-cell “proximity biotin transfer assay.” 
A.  Representative images of a western blot depicting the distribution of 
biotinylated D2R-AP into TX100 soluble (S) and insoluble (I) biochemical 
fractions. A plus sign (+) indicates that these cells were treated with the indicated 
agent, whereas a minus sign (−) indicates that these cells were not treated with 
the indicated agent. Samples in the far left lane were transfected with plasmids 
containing cDNAs for both D2R-AP and KRAS-BL, but not treated with biotin 
(biotin −). 
B.  Quantification of the relative levels of total biotinylated D2R-AP from cells 
treated with various antipsychotic drugs. Bars represent an average of the total 
biotinylated D2R-AP from cells treated with the indicated antipsychotic drug 
expressed as a fraction of the vehicle treated biotinylated D2R-AP (mean ± SEM, 
n= 4-9; * indicates p<0.05, † indicates p<0.01, compared to total biotinylated 
D2R-AP from vehicle treated cells; ANOVA followed by Dunnett’s post-hoc test). 
C. Quantification of the relative levels of biotinylated D2R-AP segregating into 
TX100 soluble and insoluble biochemical fractions from cells treated with various 
antipsychotic drugs. Bars represent an average of the soluble (white bars) or 
insoluble (black bars) biotinylated D2R-AP from cells treated with the indicated 
antipsychotic drug expressed as a fraction of the total sample biotinylated D2R-
AP (mean ± SEM, n= 4-9; * indicates p<0.05; comparing antipsychotic drug 
treated cells percent of total biotinylated D2R-AP to percent soluble biotinylated 
D2R-AP from vehicle treated cells; ANOVA followed by Dunnett’s post-hoc test). 
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D. Quantification of the total levels of biotinylated D2R-AP segregating into 
TX100 soluble and insoluble biochemical fractions from cells treated with various 
antipsychotic drugs. Bars represent an average of the soluble (white bars) or 
insoluble (black bars) biotinylated D2R-AP from cells treated with the indicated 
antipsychotic drug expressed as a fraction of the soluble biotinylated D2R-AP 
from vehicle treated cells (mean ± SEM, n= 4-9; * indicates p<0.05; compared to 
soluble biotinylated D2R-AP from vehicle treated cells; ANOVA followed by 
Dunnett’s post-hoc test). 
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Fig. 6.  Haloperidol’s effect on plasma membrane accessibility of D2R-AP 
as assessed by an in-cell “proximity-biotin transfer assay” occurs in a 
dose-dependent manner. 
A.  Upper Panels: Representative images of a western blot depicting the 
distribution of biotinylated D2R-AP into TX100 soluble (S) and insoluble (I) 
biochemical fractions. A numerical concentration indicates that these cells were 
treated with haloperidol at the indicated concentration; a plus sign (+) indicates 
that these cells were treated with biotin, and a minus sign (−) indicates that these 
cells were not treated with haloperidol or biotin. Samples in the far left lane 
originated from cells that were transfected with plasmids containing cDNAs for 
both D2R-AP and KRAS-BL, but not treated with biotin; whereas samples in the 
second image from the left were treated with biotin (+) and only vehicle (−). 
Lower Panels: Representative images of a western blot depicting the total 
cellular protein from cells that were treated identically to those lanes located in 
the images directly above (upper panels). 
B.  Quantification of the relative levels of total biotinylated D2R-AP from cells 
treated with various concentrations of the antipsychotic drug, haloperidol. Bars 
represent an average of the total biotinylated D2R-AP from cells treated with the 
indicated concentration of haloperidol expressed as a fraction of the vehicle 
treated biotinylated D2R-AP (mean ± SEM, n=4-6; † indicates p<0.01 compared 
to total biotinylated D2R-AP from vehicle treated cells; ANOVA followed by 
Dunnett’s post-hoc test). 
91 
C. Quantification of the relative levels of biotinylated D2R-AP segregating into 
TX100 soluble biochemical fractions from cells treated with various 
concentrations of haloperidol. Bars represent an average of the soluble 
biotinylated D2R-AP from cells treated with the indicated concentration of 
haloperidol expressed as a fraction of the vehicle soluble biotinylated D2R-
AP (mean ± SEM, n= 4-6; * indicates p<0.05, † indicates p<0.01 compared to 
soluble biotinylated D2R-AP from vehicle treated cells; ANOVA followed by 
Dunnett’s post-hoc test). 
D. Quantification of the relative levels of biotinylated D2R-AP segregating into 
TX100 insoluble biochemical fractions from cells treated with various 
concentrations of haloperidol. Bars represent an average of the insoluble 
biotinylated D2R-AP from cells treated with the indicated concentration of 
haloperidol expressed as a fraction of the vehicle insoluble biotinylated D2R-
AP (mean ± SEM, n= 4-6; * indicates p<0.05, † indicates p<0.01; compared 
soluble biotinylated D2R-AP from vehicle treated cells; ANOVA followed by 
Dunnett’s post-hoc test). 
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Fig 7.  Time course of haloperidol’s effect on plasma membrane 
accessibility of D2R-AP as assessed by an in-cell “proximity-biotin transfer 
assay.” 
A.  Upper Panels: Representative images of a western blot depicting the 
distribution of biotinylated D2R-AP into TX100 soluble (S) and insoluble (I) 
biochemical fractions. A time value indicates that these cells were treated with 
haloperidol for the indicated duration, a plus sign (+) indicates that these cells 
were treated with biotin, and a minus sign (−) indicates that these cells were not 
treated with haloperidol or biotin. Samples in the far left lane originated from cells 
that were transfected with plasmids containing cDNAs for both D2R-AP and 
KRAS-BL, but not treated with biotin; whereas samples in the second image from 
the left were treated with biotin (+) and only vehicle (−). Lower Panels: 
Representative images of a western blot depicting the total cellular protein from 
cells that were treated identically to those lanes located in the images directly 
above (upper panels). 
B.  Quantification of the relative levels of total biotinylated D2R-AP from cells 
treated with haloperidol, for the indicated duration. Bars represent an average of 
the total biotinylated D2R-AP from cells treated with the indicated concentration 
of haloperidol expressed as a fraction of the vehicle treated biotinylated D2R-
AP (mean ± SEM, n=3; † indicates p<0.01; compared to total biotinylated D2R-
AP from vehicle treated cells; ANOVA followed by Dunnett’s post-hoc test). 
C.  Quantification of the relative levels of biotinylated D2R-AP segregating into 
TX100 soluble biochemical fractions from cells described above.  Bars represent 
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an average of the soluble biotinylated D2R-AP from cells treated with the 
indicated concentration of haloperidol expressed as a fraction of the vehicle 
soluble biotinylated D2R-AP (mean ± SEM, n=3; † indicates p<0.01; compared to 
vehicle treated cells; ANOVA followed by Dunnett’s post-hoc test). 
D.  Quantification of the relative levels of biotinylated D2R-AP segregating into 
TX100 insoluble biochemical fractions from cells described above. Bars 
represent an average of the insoluble biotinylated D2R-AP from cells treated with 
haloperidol for the indicated interval expressed as a fraction of the vehicle 
insoluble biotinylated D2R-AP ((mean ± SEM, n=3; * indicated p<0.05, † 
indicates p<0.01; compared to vehicle treated cells; ANOVA followed by 
Dunnett’s post-hoc test). 
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Fig. 8.  High-concentration clozapine treatment D2R-AP prevents 
haloperidol-induced enhancement of D2R-AP accessibility as measured by 
an in-cell “proximity biotin transfer assay. 
A.  Upper Panels: Representative images of a western blot depicting the 
distribution of biotinylated D2R-AP into TX100 soluble (S) and insoluble (I) 
biochemical fractions. A plus sign (+) indicates that these cells were treated with 
the indicated reagent, and a minus sign (−) indicates that these cells were not 
treated with the indicated reagent. Samples in the far left lane originated from 
cells that were transfected with plasmids containing cDNAs for both D2R-AP and 
KRAS-BL, but not treated with biotin; whereas samples in the second image from 
the left were treated with biotin (+) and only vehicle (−). Lower Panels: 
Representative images of a western blot depicting the total cellular protein from 
cells that were treated identically to those lanes located in the images directly 
above (upper panels). 
B.  Quantification of the relative levels of total biotinylated D2R-AP from cells the 
antipsychotic drug, haloperidol or clozapine, or haloperidol and clozapine, for the 
indicated duration. Bars represent an average of the total biotinylated D2R-AP 
from cells treated with the indicated antipsychotic drug(s) expressed as a fraction 
of the vehicle treated biotinylated D2R-AP (mean ± SEM, n= 3-5; * indicates 
p<0.05; comparing drug treated cells total biotinylated D2R-AP to total 
biotinylated D2R-AP from vehicle treated cells). 
C.  Quantification of the relative levels of biotinylated D2R-AP segregating into 
TX100 soluble biochemical fractions from cells described above.  Bars represent 
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an average of the soluble biotinylated D2R-AP from cells treated with the 
indicated concentration of haloperidol expressed as a fraction of the vehicle 
soluble biotinylated D2R-AP (mean ± SEM, n= 3-5; † indicates p<0.01; 
comparing haloperidol treated cells soluble biotinylated D2R-AP to soluble 
biotinylated D2R-AP from vehicle treated cells). 
D.  Quantification of the relative levels of biotinylated D2R-AP segregating into 
TX100 insoluble biochemical fractions from cells described above. Bars 
represent an average of the insoluble biotinylated D2R-AP from cells treated with 
haloperidol for the indicated interval expressed as a fraction of the vehicle 
insoluble biotinylated D2R-AP ((mean ± SEM, n= 3-5; * indicates p<0.05, † 
indicates p<0.01; comparing haloperidol treated cells insoluble biotinylated D2R-
AP to insoluble biotinylated D2R-AP from vehicle treated cells). 
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Fig. 9. Representative diagram of effects of antipsychotic drugs on the 
surface expression and accessibility of plasma membrane targeted D2R. 
A.  Diagrammatic representation of the effects of antipsychotic drugs on the 
plasma membrane targeting of D2R.  Upper panel: Prior to antipsychotic 
treatment D2R exists within the plasma membrane in both detergent soluble 
(white shaded) and detergent insoluble (black shaded) regions of the plasma 
membrane. Lower Panel: Upon treatment with antipsychotic agents the total 
amount of surface receptors increases, yet the approximate proportion of soluble: 
insoluble surface receptors are maintained. 
B. Diagrammatic representation of the effects of haloperidol on the plasma 
membrane compartmentalization of D2R-AP. Upper Panel: Similar to wild-type 
D2R, D2R-APs exist both within TX100 soluble and insoluble biochemical 
fractions of the plasma membrane, whereas the plasma membrane targeted 
biotin ligase exists predominantly within TX100 soluble biochemical fractions of 
the plasma membrane. Middle Panel: Upon treatment of cells expressing both 
the D2R-AP and biotin ligase fusion proteins with biotin, the D2R-AP in the 
TX100 soluble biochemical fraction is labeled with biotin, but D2R-AP is not 
biotinylated in the TX100 insoluble biochemical fraction of the plasma membrane. 
Bottom Panel: Haloperidol enables a significant pool of the plasma membrane 
targeted D2R-AP to the TX100 insoluble biochemical fraction to become 
biotinylated, thereby disrupting the membrane compartmentalization of the 
insoluble form of D2R-AP 
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